Document:

exv10w59

Exhibit 10.59

EMPLOYMENT CONTRACT

THE UNDERSIGNED PARTIES,

	1.	 	Trident Microsystems (Nederland) B.V., having its registered office and business
address at Nijmegen, the Netherlands, duly represented by David L. Teichmann, hereinafter
referred to as “the Employer”; and
	 
	2.	 	Philippe Geyres, born on 5 September 1952, residing at 63 Rue Des Saints-Peres, 75006
Paris, France, hereinafter referred to as “the Employee”;

DECLARE THAT THEY HAVE AGREED AS FOLLOWS.

Clause 1 — Commencement and Duration

	1.1	 	The Employee will enter into the Employer’s service on 1 April 2011 on the basis of a
temporary employment contract for the duration of 9 (nine) months and which employment
contract will therefore end by operation of law on 31 December 2011. Before starting work, the
Employee shall provide the Employer with all data required to report the Employee to the tax
authorities.
	 
	1.2	 	Either party may give notice of premature termination with respect to this employment
contract, provided that such is done in writing and with due observance of the statutory
notice period. The notice period must end on the last day of a calendar month.
	 
	1.3	 	This employment contract will in any case end without any prior notice of termination being
required on the first day of the month in which the Employee reaches the statutory pension
age.

Clause 2 — Post and Duties

	2.1	 	Within the framework of this employment, the Employee will hold the post of Interim Chief
Executive Officer. The Employee’s duties, which include among others travelling overseas, are
further described in Annex 1. Employee shall report directly to and be accountable to the
Board of Directors of Trident Microsystems, Inc. (“the Board of Directors).
	 
	2.2	 	The Employee must carry out his duty to the best of his ability and with due observance of
the instructions and orders reasonably issued by the Employer. Furthermore, the Employer may
instruct the Employee to carry out work for an enterprise affiliated with the Employer. Any
such work will be governed by the rights and duties laid down in this employment contract,
without such resulting in any additional remuneration for the Employee.
	 
	2.3	 	The Employee shall carry out the work in the Employer’s office in Nijmegen, the Netherlands.
To the extent necessary, the Employer may change the place of work.

Employment contract Trident Microsystems (Nederland) B.V./Philippe Geyres

1

 

Clause 3 — Working Hours

	3.1	 	The Employee shall carry out the work during 40 hours a week, but is willing to carry out
work beyond the number of working hours set if such is required on the basis of his duties,
without any additional remuneration being paid.

Clause 4 — Salary, and Other Compensation and Holiday Allowance

	4.1	 	The Employee was previously employed by Trident Digital Systems (UK) Ltd (“Trident UK”)
pursuant to an offer letter dated January 21, 2011 (the “Offer Letter”). Employer hereby
assumes the obligations of Trident UK under the Offer Letter, including each of paragraphs 1-9
therein and Employee hereby confirms his agreement that those terms shall continue to apply.
Employee’s salary, as specified in the Offer Letter, includes a holiday allowance of 8%, and
Employee’s salary shall be payable on the last day of each month. References in the Offer
Letter to “Executive Director” shall hereafter be deemed to refer to “Interim Chief Executive
Officer.”
	 
	4.2	 	Employee acknowledges that the obligations of Trident UK shall terminate upon the
effectiveness of this Agreement.
	 
	4.3	 	Parties shall jointly file a request for application of the 30% ruling (tax-free
reimbursement for extraterritorial costs) with the Dutch Tax Inspector. Further appointments
with respect to the 30% ruling are laid down in Annex 2.

Clause 5 — Illness

	5.1	 	In the event of incapacity to work due to illness, employee must inform his superior thereof
before 9:30 a.m. on the first day of incapacity to work.
	 
	5.2	 	In case of occupational disability, the Employee will be entitled to 100% of his last-earned
gross salary, (which includes 8% holiday allowance), less any benefits to which he is entitled
within the framework of his occupational disability, during the duration of this temporary
employment contract, but in any case until the end of his employment at the latest.
	 
	5.3	 	For the purposes of this clause, periods of occupational disability succeeding one another
with interruptions of no more than four weeks will be considered one single period of
occupational disability.
	 
	5.4	 	During the Employee’s occupational disability, the Employer will at all times have the right
to verify the disability via a medical or “ARBO” service (a service set up under the Dutch
Working Conditions Act [Arbeidsomstandighedenwet, “ARBO-wet”]) designated by the Employer. The
Employee will be required to provide all information necessary to be able to establish the
right to continued salary payments during illness. Furthermore, the Employee will be required
to carry out suitable work during illness. The Employee shall comply with the Employer’s
verification regulations in case of illness.

Clause 6 — Holiday

	6.1	 	The Employee will be pro rata entitled to 25 days’ holiday for the duration of this temporary
employment contract.
	 
	6.2	 	Upon consultation with the Employer, the Employee shall determine the start and end dates of
the holiday.

Employment contract Trident Microsystems (Nederland) B.V./Philippe Geyres

2

 

	6.3	 	If upon termination of the employment contract the Employee has enjoyed more holidays than
the number accrued during the employment contract, the Employer has the right to reclaim the
Employee’s salary with respect to those holidays and to set it off against any amounts payable
to the Employee by the Employer.

Clause 7 — Pension

	7.1	 	If and insofar as he satisfies the conditions, the Employee will participate in the
Employer’s (semi) collective pension scheme, in conformity with the provisions laid down in
the pension scheme rules and regulations, a copy of which will be provided to the Employee.
The Employee declares that he has taken cognizance of the rules and regulations and will
fulfil any obligations laid down therein. The total cost of benefits, including under this
Clause 7 and Clause 9, that Employer will pay may not exceed 125% of the cost of benefits that
Trident Microsystems, Inc. would pay for a permanent CEO located in the U.S. If such amount
would be exceeded, it is the intention of the parties that the benefits payable hereunder will
be reduced in scope and expense accordingly to the fullest extent permissible under applicable
law.

Clause 8 — Reimbursement of Costs

	8.1	 	Any business expenses reasonably incurred by the Employee in connection with performing his
duties that are not deemed to qualify as costs otherwise reimbursed will be reimbursed to the
Employee by the Employer on submission of original invoices and proofs of payment if and
insofar as such costs are reasonable, in the Employer’s exclusive opinion.
	 
	8.2	 	The Employer shall make a laptop computer available to the Employee. The Employee shall look
after the laptop computer as may be expected of a prudent Employee. The Employee declares that
he will not leave the lap-top computer unsupervised under any circumstances in a car or in the
boot of a car, or in a place accessible to third parties.

Clause 9 — Insurance

	9.1	 	The Employer shall fulfil its obligation under the Dutch Health Care Insurance Act
[Zorgverzekeringswet] by remitting the Employee’s statutorily determined contribution.
	 
	9.2	 	It will be up to the Employee to ensure that the required forms are completed on time and in
full, and that cooperation is rendered in any other formalities required to participate in the
insurance referred to in Clause 9.1.

Clause 10 — Ancillary Jobs and Gifts

	10.1	 	The Employee may not hold any ancillary jobs, whether for remuneration or otherwise, without
the Employer’s prior written permission.
	 
	10.2	 	The Employee shall refrain from accepting any remuneration from third parties in connection
with the work for the Employer and/or enterprises affiliated with the Employer.

Employment contract Trident Microsystems (Nederland) B.V./Philippe Geyres

3

 

Clause 11 — Breach

	11.1	 	Should the Employee breach any of the obligations set forth in Clause 10 of this employment
contract, the Employee will promptly forfeit to the Employer, an immediately payable penalty
of EUR 5,000.-, which amount will increase by EUR 500.- for each day that the breach
continues, without prejudice to the Employer’s right to demand performance of this employment
contract. Instead of imposing a penalty, the Employer may, without issuing a notice of
default, claim full damages.
	 
	11.2	 	Payment of the penalty referred to in this clause will not release the Employee from the
obligations contained in Clause 10 of this contract.
	 
	11.3	 	Any breach by the Employee of the obligations set forth in Clause 10 will constitute an
urgent reason on the grounds of which the Employer may terminate this employment contract with
immediate effect.
	 
	11.4	 	Paragraphs 3, 4 and 5 of Section 7:650 of the Dutch Civil Code do not apply to this
employment contract.

Clause 12 — Unilateral amendment clause

	12.1	 	Within reason, the Employer is entitled to unilaterally amend the provisions of this
employment contract and/or the provisions set out in the personnel handbook and/or other
schemes. All amendments, cancellations or supplements will always be binding on the Employee.
In addition, the Employer reserves the right to unilaterally adjust (tax-free) allowances in
the event of amendments to tax and/or social security legislation.

Clause 13 — Returning Property

	13.1	 	Upon the end of this employment contract, regardless of how and why this employment contract
ended, and in the event that the Employee is placed on non-active service, the Employee must,
even without being so requested, make available to the Employer any and all items in his
possession that belong to the Employer and/or any enterprises affiliated with it and the
Employee’s working there, clients and any other business relations (including, for instance,
laptop, documents or other data carriers made available, as well as any and all copies taken
of such records), all this in the broadest meaning of the words.

Clause 14 — Final Provisions

	14.1	 	This employment contract is governed by Dutch law. Any disputes between the parties will be
submitted to the competent Dutch court.
	 
	14.2	 	Should a court declare any provision of this employment contract to be non-binding, the
parties will replace such provision by another, legally valid provision, which will correspond
to the provision declared non-binding to the greatest extent possible. The non-bindingness of
any provision of this employment contract will not affect the legal validity of the other
provisions.
	 
	14.3	 	This employment contract sets forth all obligations of the parties in respect of each other
and replaces all prior negotiations, commitments and/or correspondence.

Employment contract Trident Microsystems (Nederland) B.V./Philippe Geyres

4

 

Thus agreed and signed in duplicate:

	 	 	 	 	 	 	 

	Agreed:

	 	 
	 	Agreed:
	 	 
	 
	 	 	 	 	 	 
	/s/ David L. Teichmann
 

	 	 
	 	/s/ Philippe Geyres
 

	 	 
	On behalf of Trident Microsystems (Nederland) B.V.
	 	 	 	Philippe Geyres	 	 
	David L. Teichmann

	 	 	 	 	 	 
	Managing Director
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Date Signed: April 1, 2011

	 	 	 	Date Signed: April 4, 2011	 	 
	Place
Signed: Sunnyvale, California

	 	 	 	Place Signed: Sunnyvale, California	 	 

Employment contract Trident Microsystems (Nederland) B.V./Philippe Geyres

5

 

ANNEX 2

TRIDENT MICROSYSTEMS (NEDERLAND) B.V., a private company with limited liability (besloten
vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the Netherlands, having
its registered office in Nijmegen and its principal place of business at Kerkenbos 10-16F (6546 BA)
Nijmegen (the “Company”);

and

Mr. Philippe
Geyres, an individual born on 5 September 1952 and residing at 63 Rue Des Saints-Peres,
75006 Paris, France, (the “Employee”)

WHEREAS;

	(a)	 	On the date hereof, the Company and the Employee have entered into an employment agreement
effective 1 April 2011 (the “Start Date”);
	 
	(b)	 	the Employee is recruited outside the Netherlands by the Company;
	 
	(c)	 	the Employee and the Company shall jointly file a request for application of the 30% ruling
(tax-free reimbursement for extraterritorial costs) with the Dutch Tax Inspector;
	 
	(d)	 	in view hereof, the Employee and the Company wish to agree upon the remuneration of the
Employee as follows.

THE PARTIES HEREBY AGREE AS FOLLOWS:

	1.	 	If and to the extent that the Employee receives a tax-free reimbursement for extraterritorial
expenses based on Section 9 of the 1965 Wages and Salaries Tax Implementation Decree
(Uitvoeringsbesluit loonbelasting 1965), it is agreed that the pay for present employment
agreed with the Employee will be reduced for wage tax act (Wet op de loonbelasting 1964)
purposes in such a way that 100/70 of the thus agreed pay for present employment is equal to
the originally agreed pay for present employment.
	 
	2.	 	If and to the extent that the above under (1.) is applied, the Employee shall receive from
the Company a reimbursement for extraterritorial expenses equal to 30/70 of the thus agreed
pay for present employment.
	 
	3.	 	The Employee is aware of the fact that adjustment of the agreed remuneration pursuant to the
above under (1.) may in view of the applicable regulations have consequences for all
pay-related benefits and payments such as pension payments and social security benefits.

1/2

 

	4.	 	The “agreed pay for present employment” as described under (1.) above includes the total sum
of all pay for present employment, paid or provided to the Employee, as described in the 1964
Wages and Salaries Tax Act (Wet loonbelasting 1964) and the provisions based on it.
	 
	5.	 	The allowance will be provided as from the Start Date, up to and including the last month the
30%-ruling (or a new subsequent rule under Dutch tax legislation) will be applicable to the
Employee. This agreement will also come to an end as from the date the employment contract
between the Employee and the Company will be terminated.
	 
	6.	 	The Company reserves the right to modify or supplement this agreement if Dutch tax laws with
respect to the 30%-ruling are adjusted.

Both parties agree to the aforementioned and state that this agreement can be considered as an
addition to the employment contract.

Thus agreed and signed in duplicate:

	 	 	 	 	 	 	 

	Agreed:

	 	 
	 	Agreed:
	 	 
	 
	 	 	 	 	 	 
	/s/ David L. Teichmann
 

	 	 
	 	/s/ Philippe Geyres
 

	 	 
	On behalf of Trident Microsystems (Nederland) B.V.
	 	 	 	Philippe Geyres	 	 
	David L. Teichmann

	 	 	 	 	 	 
	Managing Director
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Date Signed: April 1, 2011

	 	 	 	Date Signed: April 4, 2011	 	 
	Place
Signed: Sunnyvale, California

	 	 	 	Place Signed:  Sunnyvale, California	 	 

2/2exv10w60

Exhibit 10.60

Execution Copy

 

AMENDED AND RESTATED

STOCKHOLDER AGREEMENT

by and between

TRIDENT MICROSYSTEMS, INC.

and

NXP B.V.

Dated as of April 28, 2011

 

 

 

AMENDED AND RESTATED STOCKHOLDER AGREEMENT

     THIS AMENDED AND RESTATED STOCKHOLDER AGREEMENT (the “Agreement”) is entered into as of April
28, 2011, (the “Amendment Date”) by and between Trident Microsystems, Inc., a Delaware corporation
(the “Company”) and NXP B.V., a Dutch besloten venootshap (the “Investor”). Capitalized terms used
but not defined herein shall have the meanings ascribed to them in Exhibit A.

RECITALS

     WHEREAS, the Company and Investor entered into a Stockholder Agreement (the “Original
Agreement”) as of February 8, 2010 (the “Agreement Date”) and now desire to amend and restate the
Original Agreement in its entirety.

     WHEREAS, the Company, Trident Microsystems (Far East) Ltd. and the Investor entered into a
Share Exchange Agreement, dated as of October 4, 2009 (the “Share Exchange Agreement”), pursuant to
which (1) Trident Microsystems (Far East) Ltd. acquired the outstanding equity securities of the
Companies and the Transferred Newcos (as defined in the Share Exchange Agreement) and certain
assets from the Investor, (2) the Company issued and Trident Microsystems (Far East) Ltd.
transferred and sold in consideration therefor, and the Investor acquired, shares of the Company’s
common stock, $0.001 par value per share, (3) the Company issued and sold, and the Investor has
purchased for cash, additional shares of such Common Stock, and (4) pursuant to the transactions
contemplated by clauses (2) and (3), the Company issued an aggregate of one hundred and four
million two hundred and four thousand three hundred and forty eight (104,204,348) shares of such
Common Stock (the “Common Shares”) and four (4) shares of the Company’s Series B Preferred Stock,
par value $0.001 per share (the “Series B Shares”);

     WHEREAS, the parties desire to enter into this Agreement to provide for certain arrangements
relating to the Company, the Common Shares and the Series B Shares; and

     NOW, THEREFORE, in consideration of the foregoing recitals and of the mutual promises
hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties hereto agree as follows:

ARTICLE 1

CORPORATE GOVERNANCE AND INFORMATION RIGHTS

     Section 1.1 Board and Committee Representation.

          (a) Board Composition.

               (i) For so long as the Persons who Own the Series B Shares (the “Series B Holders”) shall be
entitled to nominate and elect at least one (1) Director pursuant to the Certificate of
Designation, the Board shall consist of a number of Directors of seven (7) to nine (9) with the
specific number of Directors at any time to be fixed by the Board by the

 

 

adoption of a resolution by a majority of the number of Directors then in office (whether or
not there exist any vacancies in the previously authorized number of directorships at the time such
resolution is presented). The Board shall at all times consist of at least a majority of Directors
who are Independent Directors.

               (ii) Pursuant to and on the terms and conditions set forth in the Certificate of Designation,
the Series B Holders (by majority vote of the Series B Shares) shall be entitled to nominate and
elect up to two (2) Directors (each, a “Series B Director”). The number of Series B Directors
shall be reduced from time to time as provided in the Certificate of Designation. The remaining
Directors (the “Company Nominated Directors”) shall be recommended by the Nominating and Corporate
Governance Committee, nominated by the Board and from time to time shall be submitted to the
Company’s stockholders for election in accordance with the Company’s Certificate of Incorporation
and Bylaws.

               (iii) Immediately following the Amendment Date, the Series B Holders (by majority vote of the
Series B Shares) shall be entitled to designate a total of two (2) Series B Directors, one (1) of
whom shall be a member of the class of Directors whose term expires at the first annual meeting of
the Company’s stockholders following the Amendment Date and one (1) of whom shall be a member of
the class of Directors whose term expires at the second annual meeting of the Company’s
stockholders following the Amendment Date.

          (b) Notifications Regarding Directors.

               (i) The Series B Holders will notify the Company in writing promptly, and in any event within
five (5) Business Days, of any action by the Series B Holders or any of their Affiliates (other
than the Company) that results in a reduction in the number of shares of Common Stock that are
Beneficially Owned by the Series B Holders representing, individually or together with all such
reductions since the date of the filing of the Certificate of Designation with the Secretary of
State of the State of Delaware or the date of any previous such notice, as applicable, one percent
(1%) or more of the outstanding Common Stock as of the date of such filing or such previous notice,
which notice will set forth the number of shares of Common Stock Beneficially Owned by the Series B
Holders immediately following the occurrence of such reduction; provided, that for purposes of this
provision, in determining the shares of Common Stock outstanding the Series B Holders may rely upon
the Company’s most recent periodic report filed with the SEC, or any update thereof, or any notice
provided by the Company pursuant to Section 1.1(b)(iii) below. In the event that the number of
Directors that the Series B Holders are entitled to nominate and elect to the Board is reduced
pursuant to Section 4(a) of the Certificate of Designation, the Series B Holders shall promptly
cause one (1) or more of the Series B Directors to immediately resign, such that the number of
remaining Series B Directors serving on the Board shall equal the number of Directors that the
Series B Holders are then entitled to elect to the Board pursuant to such Section 4(a) of the
Certificate of Designation. In the event that the number of Series B Directors required to resign
are unwilling to resign, the Series B Holders will take all such actions as are necessary to cause
the removal of the required number of such Series B Directors. If such number of Series B
Directors shall not have resigned or been removed within thirty (30) days after the date on which
such resignation was required, the Company Nominated Directors, by majority vote, may remove the
Series B Director(s) selected by the Series B Holders for removal, or if no such Series B Directors
have been so

2

 

selected by the Series B Holders within ten (10) Business Days of a request from the Company,
the Company Nominated Directors, by majority vote, may remove one or more Series B Directors
selected by them, such that, in the aggregate, the number of Series B Directors required to resign
under this Section 1.1(b)(i) have been removed. Any vacancies created as a result of a reduction
in the number of Series B Directors that the Series B Holders are entitled to elect pursuant to
Section 4(a) of the Certificate of Designation shall be filled by nominees (A) who satisfy the
requirements of Section 1.1(c), and (B) are recommended by the Nominating and Corporate Governance
Committee and approved by the Board. The Director(s) appointed to fill such vacancy shall stand
for re-election at the next annual meeting of the Company’s stockholders and shall, if elected,
serve for the remaining term of the Series B Director(s) that such Director(s) replaced.

               (ii) The Series B Holders shall notify the Company in writing at least ten (10) days in
advance of the anticipated date of the mailing of the Company’s proxy statement in connection with
its annual meeting of stockholders (as advised by the Company in writing to the Series B Holders
not less than twenty (20) nor more than sixty (60) days prior to such anticipated mailing date) of
the nominees to be elected as Series B Directors in the class of Directors to be elected at such
annual meeting. The Series B Holders shall, to the extent practicable, notify the Company in
writing a reasonable time in advance of any other nomination of any person to serve as Series B
Director, including for the purpose of electing or appointing a Series B Director to fill a vacancy
that the Series B Holders are entitled to fill, together, in each case, with all information
concerning such nominee that may be reasonably requested by the Company, or that may be required
for the Company to comply with its reporting obligations under the Exchange Act or Exchange listing
requirements; provided that in the absence of such notice, the Series B Holders shall be deemed to
have nominated and elected the person(s) then serving as Series B Director(s).

               (iii) The Company shall notify the Series B Holders promptly, and in any event within five (5)
Business Days, of any issuance of Common Stock representing, individually or together with all
issuances of Common Stock since the date of the filing of the Certificate of Designation with the
Secretary of State of the State of Delaware or the date of any previous such notice, as applicable,
one percent (1%) or more of the outstanding Common Stock as of the date of such filing or such
previous notice together with the aggregate number of shares of Common Stock outstanding following
such issuance.

          (c) Limitations on Directors. Each Director shall, at all times during which such
Person serves as a Director, not have been during the last five (5) years convicted in a criminal
proceeding (excluding traffic violations or other misdemeanors not involving moral turpitude or
deliberate dishonesty) or a party to a civil proceeding brought by a Governmental Authority in
which such Director has been finally determined to have committed a violation of federal, state or
foreign law (excluding traffic violations or similar misdemeanors not involving moral turpitude or
deliberate dishonesty). The Series B Holders shall not nominate or elect any such Series B
Director who does not meet the requirements set forth in this Section 1.1(c) and shall cause any
such Series B Director who fails to meet the requirements set forth above to resign promptly. If
any such Series B Director is unwilling to resign, the Series B Holders will take such actions as
are necessary to cause the removal of the Series B Director as promptly as reasonably practicable.

3

 

          (d) Limitations on Series B Directors. Each of the Series B Directors shall have
substantial operating or industry experience and shall be a Person who is an Independent Director.
The Series B Holders shall consult with the Nominating and Corporate Governance Committee (which
may delegate such consultation to the Committee Chairperson and/or the Chief Executive Officer of
the Company) regarding the names, backgrounds and qualifications of the persons to be nominated as
Series B Directors after considering the Company’s Corporate Governance Guidelines (as made
publicly available from time to time). However, the Nominating and Corporate Governance Committee
shall not have any right nor shall it have any duty to approve or disapprove any person meeting the
requirements of Section 1.1(c) selected as a Series B Director by the Series B Holders.

          (e) Limitations on Company Nominated Directors. No more than one (1) Company
Nominated Director may be a Person who is not an Independent Director. At least two (2) of the
Company Nominated Directors shall have substantial operating or industry experience.

     Section 1.2 Board Committees.

          (a) Subject to the requirements of applicable law and Committee Qualification Requirements
applicable to all Directors, for as long as there is at least one (1) Series B Director on the
Board, the Company shall maintain an Audit Committee, a Compensation Committee and a Nominating and
Corporate Governance Committee. Subject to the terms set forth in this Section 1.2, the power and
authority of each such committee shall be as set forth in the charter of such committee, and
(except as otherwise provided in the charter of such committee or as required by applicable law or
any applicable Exchange rules) the exercise of such power and authority will be at all times
subject to the power and authority of the entire Board.

          (b) Any Directors appointed to a committee or subcommittee of the Board who are not Series B
Directors shall be recommended by the Nominating and Corporate Governance Committee and appointed
by the Board. If the members of the Nominating and Corporate Governance Committee are unable to
agree on any committee or subcommittee assignment, the Chairman of the Board shall act as a
temporary member of the Nominating and Corporate Governance Committee for purposes of casting the
deciding vote on such matter.

          (c) Except for (i) routine commercial transactions entered into on an arms’ length basis in
the ordinary course of business, (ii) contracts or arrangement involving expenditures, revenues or
the incurrence of liabilities not in excess of $50,000, and (iii) the transactions contemplated by
the Share Exchange Agreement, the entry into, termination or variation of any contract or
arrangement between the Company and any Related Party shall be approved by the affirmative vote of
a majority of the disinterested Directors. For purpose of this Section 1.2(c), a “Related Party”
includes the Directors and officers of the Company, the spouses or children of such Directors and
officers, the Investor, any of the Series B Holders, any other stockholder that (together with its
Affiliates) Beneficially Owns more than ten percent (10%) of the outstanding Voting Stock of the
Company, or any Affiliate of any of the foregoing.

4

 

          (d) Notwithstanding the foregoing, any Board committee may hold executive sessions at which
one (1) or more Directors is not permitted to be present to the extent the
committee determines in good faith that such exclusion is appropriate.

     Section 1.3 Voting.

          (a) Change of Control Transactions. Subject to compliance with Section 1.3(c),
Section 1.3(d) and Section 3.2, the Investor and its Affiliates may vote any Voting Stock
Beneficially Owned by any of them in their sole discretion on any Change of Control transaction
submitted to the stockholders of the Company for approval, provided that on and after the fourth
anniversary of the date of this Agreement, the Investor may, notwithstanding Section 1.3(c) or
Section 1.3(d) hereof, but subject to compliance with Section 3.2 hereof, vote in its discretion on
any proposal to replace Directors that is made by an unaffiliated third party in connection with a
Change of Control transaction proposed by such unaffiliated third party.

          (b) Amendments to Certificate of Incorporation or Bylaws; Amended and Restated Certificate
of Incorporation. The Investor and its Affiliates may vote the Voting Stock Beneficially Owned
by any of them on any proposal related to any amendment or restatement of the Certificate of
Incorporation or Bylaws of the Company which is in any way adverse to the Investor in their sole
discretion. Investor agrees to vote its shares of Preferred Stock and its Voting Stock in favor of
the Amended and Restated Certificate of Designation set forth on Exhibit D.

          (c) Stockholders Agreement. The Investor shall, and shall cause its Permitted
Transferees to and shall use commercially reasonable efforts to cause its Affiliates to, vote the
Voting Stock Beneficially Owned by any them in favor of each matter required to effectuate any
provision of this Agreement and against any matter the approval of which would be inconsistent with
any provision of this Agreement.

          (d) Directors. With respect to the election, removal, replacement and classification
of Directors (other than Series B Directors) the Investor and its Affiliates shall either (i) vote
all of the Voting Stock Beneficially Owned by any of them in accordance with the recommendation of
the Board approved by a majority of the Company Nominated Directors or (ii) vote all of the Voting
Stock Beneficially Owned by any of them in the same proportion (for, against, abstain or withheld,
or as otherwise indicated) as the votes cast by all other holders of Voting Stock.

          (e) Other Matters. Except as provided in Sections 1.3(a), 1.3(b), 1.3(c) and 1.3(d),
for so long as the Investor and its Affiliates in the aggregate Beneficially Own in excess of
thirty percent (30%) of the outstanding Voting Stock of the Company (the “Voting Limit”), the
Investor shall, and shall cause its Affiliates to, either (i) vote all of the Voting Stock
Beneficially Owned by any of them in excess of the Voting Limit in accordance with the
recommendation of the Board approved by a majority of the Company Nominated Directors or (ii) vote
all of the Voting Stock Beneficially Owned by any of them in excess of the Voting Limit in the same
proportion (for, against, abstain or withheld, or as otherwise indicated) as the votes cast by all
other holders of Voting Stock on all matters to be voted on by holders of Voting Stock. Subject to
the other provisions of this Agreement, the Investor and its Affiliates may vote

5

 

the Voting Stock
Beneficially Owned up to and including (but not in excess of) the Voting Limit on any proposal in
its sole discretion.

          (f) Quorum. At every meeting (or action by written consent, if applicable) of the
stockholders of the Company called, and at every postponement or adjournment thereof, the Investor
shall, and shall cause its Affiliates to, cause any and all shares of Common Stock Beneficially
Owned by it or them and entitled to be voted thereat to be present in person or represented by
proxy at the meeting so that all such shares shall be counted as present for purposes of
determining the presence of a quorum at such meeting.

     Section 1.4 Information Rights.

          (a) Subject to Section 1.5, the Company will deliver to the Investor the following
information:

               (i) with respect to each fiscal year: (A) promptly after it has been made available (but in no
event later than fifteen (15) Business Days of the end of each fiscal year) the unaudited
consolidated financial statements of the Company and its Subsidiaries, (B) promptly after it has
been made available (but in no event later than twenty-five (25) Business Days of the end of each
fiscal year) the audited consolidated financial statements of the Company and its Subsidiaries,
audited in accordance with U.S. GAAS, and (C) promptly after it has been made available (but in no
event later than seventy (70) Business Days of the end of each fiscal year) the international
financial reporting standards (“IFRS”) consolidated financial statements of the Company and its
Subsidiaries; provided, that if the Company properly extends the date for filing of any such
statements specified in subparagraph (B) or (C) above with the SEC (i.e., by means of a filing on
Form 12b-25), then the date set forth above for delivery to the Investor shall be extended for a
corresponding period;

               (ii) with respect to each quarterly period, promptly after it has been made available,
quarterly unaudited U.S. GAAP consolidated financial statements of the Company and its
Subsidiaries, including (i) a detailed profit and loss statement, balance sheet and cash flow
statement (which may be unreviewed and subject to further adjustment) to be provided within ten
(10) Business Days of the end of each quarter, (ii) such information as may reasonably be required
for the Investor to prepare an update of the IFRS reconciliation for net income and shareholders
equity, (iii) a management discussion & analysis, including an analysis of revenue, (iv) a rolling
forecast in relation to the current quarter as presented to the Board of Directors and (vi)
financial information on related party matters, which information shall, to the extent possible, be
directly extracted from the Company‘s information technology systems;

               (iii) with respect to each monthly period, promptly after it has been made available (but in
no event later than ten (10) Business Days of the end of each month) information including net
income and net assets and equity (which may be unreviewed and subject to adjustment) (provided,
that if such information is not delivered earlier, estimates of such information shall be made
available within seven (7) Business Days of the end of each month);

6

 

               (iv) draft business plans for the Company and its Subsidiaries for the subsequent three (3)
year period no later than two (2) Business Days after approval thereof by the Board, in the form
presented to the Board (but subject to Section 1.4(b));

               (v) copies of all reports, certificates, and other information delivered to the Company’s
lenders or creditors in respect of any material indebtedness of the Company; and

               (vi) any other financial information, reports and workpapers in the possession or under the
control of the Company or any of its Subsidiaries that the Investor reasonably requires to comply
with reporting, disclosure, filing or other requirements imposed on the Investor or any of its
Subsidiaries (A) by a Governmental Authority having jurisdiction over the Investor or any of its
Subsidiaries, including under applicable securities or tax laws, including the Sarbanes-Oxley Act
of 2002, as amended, (B) by IFRS adopted by the International Accounting Standards Board or any
successor entity, (C) by the covenants in financing arrangements to which the Investor is a party,
and (D) the rules and regulations thereunder, or applicable rules of any self-regulatory
organization.

          (b) The Investor shall be entitled to confer with each Series B Director regarding the
business, affairs, financial condition, results of operations and prospects of the Company and may
discuss any and all information (other than confidential compensation information) provided to the
Investor or any such Series B Director, subject to Section 1.5 below; provided, that if the Board
determines in good faith that any Company information must be held in confidence in order to (i)
preserve attorney-client privilege, (ii) comply with any applicable confidentiality or
non-disclosure agreement, or (iii) prevent a dissemination of competitively sensitive information
regarding (A) products, services or other activities of the Company with respect to which the
Investor or its Subsidiaries competes with the Company or (B) proposed products, services or other
activities of the Company that the Board reasonably determines that the Company may develop,
acquire or pursue that would be competitive with the current products, services or other activities
of the Investor or any of its Subsidiaries or (C) any other matter as to which the Board has
determined in good faith that the Company and the Investor have a material conflict of interest
based on a reasonable expectation that disclosure of such information may be harmful to the
Company, then the Series B Directors shall hold such information in confidence and not discuss such
information with the Investor except to the degree, if any, approved by the Board.

     Section 1.5 Confidentiality. (a) The Investor shall keep confidential (x) all proprietary
and non-public information regarding the Company and its Subsidiaries received pursuant to Sections
1.3 or 1.4 or otherwise, (y) all “Information” (as defined in the Confidentiality Agreement)
provided to the Investor or its representatives under the Confidentiality Agreement prior to the
date hereof (notwithstanding the termination of the Confidentiality Agreement), and (z) all
non-public information furnished or disclosed to or otherwise acquired by any Series B Director in
such Person’s capacity as a Director (clauses (x), (y) and (z) collectively, “Confidential
Information”), and in each case shall not disclose or reveal any such information to any Person
without the prior written consent of the Company, other than those of its employees, officers,
directors, First Tier Affiliates, attorneys, accountants and financial advisors (“Permitted
Representatives”) who need to know such information for

7

 

the purpose of evaluating, monitoring or
taking any other action with respect to the investment by the Investor in the Common Shares or the
Series B Shares and shall cause those Permitted Representatives to observe the terms of this
Section 1.5 and agree for the benefit of the Company to do so (and any violation or breach of the
terms of this Section 1.5 by any Permitted
Representative shall be deemed a breach hereof by the Investor). Notwithstanding the
foregoing, no officer, employee or director of any Entity that is a Company Competitor shall be a
Permitted Representative, and no Confidential Information shall be furnished or disclosed to any
such Company Competitor.

          (b) The Investor shall not, and shall cause its First Tier Affiliates and Permitted
Representatives not to, use such proprietary and non-public information for any purpose other than
in connection with evaluating, monitoring or taking any other action with respect to the investment
by the Investor in the Common Shares or the Series B Shares; provided, that nothing herein shall
prevent the Investor or any of its Permitted Representatives from disclosing any such information
that (1) is or becomes generally available to the public other than as a result of a disclosure by
the Investor or its Permitted Representatives in violation of this Section 1.5 or any other
confidentiality agreement between the Company and the Investor or any of its Permitted
Representatives or any other legal duty, fiduciary duty, or other duty of trust and confidence of
the Investor, any of its Permitted Representatives, or any Series B Director, (2) was within the
Investor’s or its Permitted Representative’s possession on a non-confidential basis prior to being
furnished with such information (provided that the source of such information was not known by the
Investor at the time of such disclosure by the Investor or any of its Permitted Representatives to
be bound by a confidentiality agreement with, or other contractual, legal or fiduciary obligation
of confidentiality to or other duty of trust and confidence to, the Company with respect to such
information), (3) was independently developed by Investor without use of any information furnished
to Investor, any of its Permitted Representatives or any Series B Director, or (4) becomes
available to the Investor or its Permitted Representative on a non-confidential basis from a source
other than the Company (provided that such source is not known by the Investor at the time of such
disclosure by the Investor or any of its Permitted Representatives to be bound by a confidentiality
agreement with, or other contractual, legal or fiduciary obligation of confidentiality to or other
duty of trust and confidence to, the Company with respect to such information).

          (c) If any Confidential Information is required to be disclosed by applicable law or judicial
order, then the Investor will notify the Company in writing and will cooperate with the Company if
the Company elects to seek a protective order or other appropriate remedy with respect to such
required disclosure. If no such protective order is obtained, and if Investor or any of its
Permitted Representatives has been advised by legal counsel in writing that it is legally compelled
to disclose any Confidential Information, then the Investor or such Permitted Representative may
disclose such Confidential Information, but will furnish only that portion of the Confidential
Information which Investor or is Permitted Representatives is advised by counsel is legally
required and will exercise its reasonable efforts to obtain reliable assurance that confidential
treatment will be accorded such Confidential Information.

          (d) Upon the redemption of all of the Series B Shares and the termination of the Investor’s
right to information under Section 1.4, the Investor shall return to the Company all written
Confidential Information that has been provided to the Investor by the Company;

8

 

provided, that in
lieu of being returned to the Company such Confidential Information may be destroyed by Investor,
in which case Investor shall provide the Company with a written certification that such written
Confidential Information has been destroyed.

     Section 1.6 Major Decisions. The approval of any of the following matters shall require an
affirmative vote of at least two-thirds (2/3) of the Directors present (in person or by telephone
or video conference) and voting for or against approval of any such matter at any meeting at of
which proper notice is provided to the Board in accordance with the Company’s Bylaws (or is waived
by all Directors) and such matter is considered:

               (i) any amendment to the Company’s Certificate of Incorporation, Bylaws or any other
organizational documents of the Company;

               (ii) the consummation of any merger, business combination, consolidation, corporate
reorganization or any transaction constituting a Change of Control, by the Company with or into any
Entity;

               (iii) any sale, transfer or other disposition (including by way of issuance of Equity
Securities of a Subsidiary) of assets of the Company and its Subsidiaries in an amount in excess of
$50,000,000;

               (iv) any acquisition, capital expenditure, investment (or any commitment in respect thereof)
by the Company or any of its Subsidiaries (or series of related acquisitions, expenditures,
investments or commitments) of the assets or securities of any other Entity in an amount in excess
of $50,000,000;

               (v) any Liquidation Proceeding;

               (vi) the removal or termination of employment of the Company’s Chief Executive Officer or the
selection of a replacement of the Chief Executive Officer;

               (vii) any transactions with the Investor or any of its Affiliates that involve more than
$1,000,000 or that are otherwise material to the Company;

               (viii) any authorization or approval of any amendment to or waiver under this Agreement;

               (ix) any payment or declaration of dividends on the Company’s capital stock, special or
otherwise;

               (x) any repurchase by the Company of any of its Equity Securities in an amount exceeding
$5,000,000 in any 12-month period;

               (xi) any equity or debt financing in an amount in excess of $50,000,000; and

9

 

               (xii) any other matters requiring stockholder approval under the listing rules of the NASDAQ
Stock Market or any other Exchange on which the Common Stock is listed.

ARTICLE 2

TRANSFERS

     Section 2.1 Transfer Restrictions.

          (a) General Restriction. The Investor shall not Transfer any of the Series B Shares
or any Common Shares or other Equity Securities acquired pursuant to Section 3.1 hereof other than
as expressly permitted by, and in compliance with, the other provisions of this Section 2.1, and
any attempted Transfer in violation of this Agreement shall be of no effect and null and void, and
shall not be recorded on the stock transfer books of the Company, regardless of whether the
purported Transferee has any actual or constructive knowledge of the Transfer restrictions set
forth in this Agreement.

          (b) Two Year Lock-up Restriction.

               (i) Prior to the second anniversary of the Closing (the “Lock-up Period”), the Investor shall
not Transfer any Common Shares or other Equity Securities acquired pursuant to Section 3.1 hereof,
except that the Investor may Transfer any or all of its Common Shares or Equity Securities acquired
pursuant to Section 3.1 hereof (1) pursuant to any Approved Transaction in which stockholders of
the Company are offered, permitted or required to participate as holders of any of the Company’s
Equity Securities; (2) as a pledge of its assets pursuant to a bona fide financing transaction; or
(3) to one (1) or more First Tier Affiliates of the Investor; provided that in the case of clause
(2) or (3), any Transferee of Common Shares or other Equity Securities acquired pursuant to Section
3.1 hereof (x) agrees to be bound hereunder as an Investor, and (y) executes a counterpart to this
Agreement agreeing to the terms of this Agreement (including, without limitation, this Section 2.1
and Section 3.2) (the Transfers referred to in clauses (1) through (3) collectively referred to as
the “Exempt Transfers”). Upon a Transfer contemplated by clause (3) above, any Transferee of
Common Stock shall be deemed an Investor hereunder and shall be entitled to the rights (including,
but not limited to the registration rights pursuant to Article 4), and subject to the obligations
and restrictions (including, without limitation, the provisions of this Section 2.1 and Section
3.2), contained herein. A Transferee under any pledge permitted under clause (2) above shall be
subject to the obligations and restrictions (including, without limitation, the provisions of this
Section 2.1 and Section 3.2), contained herein and shall have the rights of an Investor with
respect to piggyback registrations under Section 4.2 below, but no other rights hereunder (and for
the avoidance of doubt, shall have no rights under Section 3.1 or Section 4.1 hereof). As used
herein, “Approved Transaction” means any tender offer, exchange offer, merger, sale of the Company,
reclassification, reorganization, recapitalization or other transaction that has been approved or
recommended by a majority of the Company Nominated Directors who are Independent Directors (and
which at the time of Transfer continues to be approved or recommended by a majority of the Company
Nominated Directors who are Independent Directors).

10

 

               (ii) Notwithstanding clause (i) above, the Investor may Transfer Common Shares or other Equity
Securities acquired pursuant to Section 3.1 hereof to one or more Persons that are Eligible
Transferees in an aggregate amount not to exceed 15% of the outstanding Voting Stock if and to the
extent that the Investor determines (after consultation with its independent registered public
accounting firm) that the Investor would otherwise be required
to consolidate the Company’s financial results in the Investor’s consolidated financial
statements prepared under IFRS or US generally accepted accounting principles. In connection with
any such Transfer, (x) the Company shall not have any obligation to register such transferred
shares under the Securities Act or any other applicable law in order to permit such Transfer, (y)
any such Transfer must comply with all of the provisions of Section 2.1(c), and (z) as a condition
to any such Transfer the Transferee must (1) agree in writing to be bound by and comply with this
Section 2.1 and (2) agree in writing to be bound by and comply with the provisions of Section 1.3
and Section 3.2 hereof until the end of the Lock-up Period (with the reference to “Standstill
Limit” to be replaced by a reference to the percentage of the outstanding Voting Stock subject to
such Transfer). Any Transferee under this Section 2.1(b)(ii) shall not be considered an Investor
under this Agreement and shall have no rights under this Agreement (including, without limitation,
under Sections 1.4, 3.1 and 4.1 hereof) other than the right to participate in Piggyback
Registrations (if any) under Section 4.2. Upon any Transfer pursuant to this Section 2.1(b)(ii),
the Standstill Limit shall immediately be permanently reduced by a number of shares of Common Stock
equal to the number of shares of Common Stock so Transferred.

          (c) Ongoing Restrictions. After the Lock-up Period, unless otherwise approved by a
majority of the Company Nominated Directors (which approval shall not be unreasonably withheld or
delayed), the Investor shall not, and shall not permit any of its Affiliates to, Transfer any
Common Stock or agree to Transfer, directly or indirectly, any Common Stock, other than any
Transfer:

               (i) that would have been an Exempt Transfer permitted during the Lock-up Period under clauses
(1), (2) or (3) of Section 2.1(b) (which, in the case of clause (3) of Section 2.1(b), the
Transferee shall be deemed an Investor hereunder and shall be entitled to the rights (including,
but not limited to the registration rights pursuant to Article 4), and subject to the obligations
and restrictions (including, without limitation, any applicable provisions of this Section 2.1 and
Section 3.2), contained herein);

               (ii) pursuant to and in compliance with the restrictions of Rule 144 under the Securities Act
applicable to sales by affiliates of an issuer;

               (iii) pursuant to a firm commitment underwritten distribution to the public, registered under
the Securities Act;

               (iv) pursuant to a distribution registered under the Securities Act (other than as provided in
clause (iii) above), in an amount not exceeding, on any trading day, 25% of the ADTV as in effect
on such trading day; or

               (v) to any Person that after consummation of such Transfer would Beneficially Own (A) in the
case of an Eligible Transferee, less than fifteen percent (15%), and

11

 

(B) in the case of an
Ineligible Transferee, less than five percent (5%), of the outstanding Voting Stock of the Company;

provided, that, in the case of a Transfer pursuant to clause (ii) or clause (iv), the Investor
shall not knowingly Transfer any shares of Common Stock to any Person that, after consummation of
such Transfer, would Beneficially Own (I) in the case of an Eligible Transferee, more than
fifteen percent (15%), and (II) in the case of an Ineligible Transferee, more than five percent
(5%), of the outstanding Voting Stock of the Company; and provided further, that in the case of a
Transfer pursuant to clause (iii) that is effected through a firm commitment underwriting, the
Investor shall instruct the underwriters to use their reasonable best efforts to (A) effect as wide
a distribution as practicable of the Common Stock Transferred, consistent with best execution
standards and (B) not knowingly sell Common Stock to any Person that, after consummation of such
Transfer, would Beneficially Own (I) in the case of an Eligible Transferee, more than fifteen
percent (15%), and (II) in the case of an Ineligible Transferee, more than five percent (5%), of
the outstanding Voting Stock of the Company.

     Any Transferee acquiring Common Stock pursuant to clauses (ii), (iii), (iv) or (v) of this
Section 2.1(c) (other than the Investor, an Affiliate of the Investor or any member of a 13D Group
of which the Investor or any of its Affiliates are members) shall take such Common Stock free of
the obligations of the Investor under this Agreement (including, without limitation, this Section
2.1 and Section 3.2) and shall have no rights as an Investor or Permitted Transferee under this
Agreement (including, without limitation, any rights under Article 1, Section 3.1 or Article 4).

          (d) Restrictions on the Series B Share. Neither the Investor nor any other Series B
Holder may Transfer any of the Series B Shares to any other Person, except that the Investor shall
have the right to Transfer Series B Shares to any Permitted Transferee that acquires twenty percent
(20%) or more of the Investor Registrable Securities in compliance with the provisions of this
Section 2.1. Upon such a Transfer, such Transferee shall be deemed an Investor and a Series B
Holder hereunder and shall be entitled to the rights, and subject to the obligations and
restrictions, contained herein.

     Section 2.2 Legends; Securities Act Compliance.

          (a) Each certificate representing Common Shares, Series B Shares or other Equity Securities
acquired by the Investor or any of its Affiliates pursuant to Section 3.1 will bear a legend
conspicuously thereon to the following effect:

“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE
SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD, PLEDGED, ASSIGNED OR
OTHERWISE TRANSFERRED UNLESS REGISTERED OR EXEMPT FROM REGISTRATION
UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS. IN ADDITION,
THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS
OF A

12

 

STOCKHOLDER AGREEMENT AND MAY NOT BE OFFERED, SOLD, PLEDGED,
ASSIGNED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH SUCH
AGREEMENT.”

          (b) In addition to the restrictions set forth in Section 2.1, the Investor shall not
offer, sell or legally transfer any Common Shares or Equity Securities acquired pursuant to
Section 3.1 hereof except pursuant to: (i) an effective Registration Statement under the Securities
Act; (ii) an opinion of legal counsel reasonably acceptable to the Company that such Transfer is
exempt from the registration requirements of Section 5 of the Securities Act; (iii) pursuant to
Rule 144 under the Securities Act; or (iv) a “no action” letter from the staff of the SEC addressed
to the Investor or a Permitted Transferee to the effect that the Transfer without registration
would not result in a recommendation by the staff to the SEC that action be taken with respect
thereto.

          (c) In the event that any Common Shares Beneficially Owned by the Investor or any of its
Affiliates is Transferred in a Public Offering as provided in Section 2.1(c)(iii) or 2.1(c)(iv),
the Company shall promptly, upon request, but in any event not later than is necessary in order to
consummate the sale of such securities pursuant to such Public Offering, remove the legend set
forth above in connection with such Transfer. In the event that any Common Shares Beneficially
Owned by the Investor or any of its Affiliates is Transferred pursuant to Rule 144 under the
Securities Act in compliance with Section 2.1(c)(ii), the Company shall upon request, upon receipt
of documentation reasonably required by the Company to confirm such Investor’s eligibility to sell
such Common Shares pursuant to Rule 144 under the Securities Act, promptly but in any event not
later than is necessary in order to consummate the sale of such securities pursuant to Rule 144
under the Securities Act (subject to receipt of such documentation a reasonable period of time
prior to such sale), remove the second sentence of the legend set forth above in connection with
such Transfer.

          (d) In the event that any Common Shares are transferable without volume or manner of sale
restrictions pursuant to Rule 144 under the Securities Act and the terms of this Article 2 no
longer restrict the Transfer of such Common Shares by the holder thereof, the Company shall
promptly upon request remove the legends set forth above from the certificates representing such
Common Shares.

          (e) Upon the termination of the restrictions set forth in Section 2.1, the Company shall
promptly, upon request, deliver a replacement certificate not containing the second sentence of the
legend set forth above.

ARTICLE 3

CERTAIN COVENANTS

     Section 3.1 Right to Maintain. During the Right to Maintain Period:

          (a) The Company shall provide the Investor the opportunity to purchase in any Offering up to
its Pro Rata Share; provided, however, in no event shall the Investor be

13

 

entitled to purchase an
amount of Equity Securities in any such Offering that would cause Section 3.2 to be violated.

          (b) No later than fifteen (15) Business Days prior to the anticipated consummation of an
Offering, the Company shall send a written notice (the “Offering Notice”) to the Investor,
indicating the material terms and conditions of the proposed Offering, including, without
limitation, (i) the number and type of Equity Securities expected to be offered or sold
and the material terms of such Equity Securities, (ii) the expected price at which it proposes
to offer or sell such Equity Securities, or the expected formula for determining such price, (iii)
the expected timing of the Offering, and (iv) the name, telephone and facsimile number or e-mail
address of the Person at the Company to whom the Investor should deliver a Response Notice (as
defined below). If, prior to the consummation of the Offering, the terms and conditions of the
proposed Offering change, with the result that the price will be less than the minimum price set
forth in the Offering Notice or the other principal terms and conditions will be materially more
favorable to potential subscribers in the Offering than those set forth in the Offering Notice, it
will be necessary for a separate Offering Notice to be furnished, and the terms and provisions of
this Section 3.1 separately complied with, in order to consummate the Offering pursuant to this
Section 3.1.

          (c) The Investor shall have the right, by providing written notice to the Company no later
than five (5) Business Days prior to the anticipated consummation of an Offering and indicating the
name, telephone number, facsimile number or e-mail address of the Person or Persons that the
underwriter(s) of the Offering should call to coordinate with respect to any sales to the Investor,
to either (i) purchase Equity Securities up to its Pro Rata Share in the Offering upon the terms
and conditions specified in the Offering Notice and upon the same terms and conditions applicable
to all other participants in such proposed Offering, or (ii) waive its right to purchase Equity
Securities up to its Pro Rata Share in the Offering (in either case, a “Response Notice”). If the
Investor or a Permitted Transferee shall fail to provide the Company with a Response Notice no
later than five (5) Business Days prior to the date of the expected Offering as set forth in the
Offering Notice, then the Investor shall not be entitled to purchase Equity Securities in the
Offering. In any event, it shall be a condition to the Investor’s or a Permitted Transferee’s
opportunity to purchase Equity Securities in an Offering that it comply with the reasonable
requests of the underwriter(s) necessary for it to purchase shares in the Offering (e.g.,
establishing an account with an underwriter in the Offering). The election by the Investor not to
exercise its rights to purchase up to its Pro Rata Share in, or failure to deliver a Response
Notice with respect to, any Offering shall not affect its rights as to future Offerings pursuant to
this Section 3.1. In the event that the Company has not sold the Equity Securities within sixty
(60) calendar days after the date of the expected Offering as set forth in the Offering Notice,
then the Company shall not thereafter issue or sell the Equity Securities without again first
complying with the provisions of this Section 3.1 and offering the Investor the right to purchase
its Pro Rata Share thereof.

          (d) For the avoidance of doubt, under no circumstances shall any pledgee of any Common Stock
or any Transferee from such pledgee be deemed an Investor for purposes of this Section 3.1, and no
such pledgee or Transferee shall have any rights under this Section 3.1.

14

 

     Section 3.2 Standstill.

          (a) For a period of six (6) years from the Closing (the “Standstill Period”), the Investor
shall not, and the Investor shall ensure that none of its Affiliates shall, nor shall any of the
foregoing Persons act in concert with any other Person to, directly or indirectly, without the
prior consent of a majority of the Company Nominated Directors who are Independent Directors:

               (i) acquire or agree to acquire (whether by purchase, tender or exchange offer, through
acquisition of control of another Person, by joining a 13D Group, through the use of a derivative
instrument or voting agreement, or otherwise), Beneficial Ownership of any Equity Securities, or
any Economic Right or Voting Right to or regarding any Equity Securities, or authorize or make a
tender offer, exchange offer or other offer or proposal, whether oral or written, to acquire Equity
Securities, in each case, if the effect of such acquisition would be that the Common Stock
Beneficially Owned in the aggregate by the Investor and its Affiliates (including, without
limitation, any 13D Group of which any Investor or any Affiliate thereof is a member), or with
respect to which the Investor, its Affiliates or any such 13D Group would have Economic Rights or
Voting Rights, would exceed the Standstill Limit (it being understood that in the event that there
shall be more than one (1) Investor, all shares Beneficially Owned and all Economic Rights and
Voting Rights held by all Investors and all other Persons that are participants in any 13D Group of
which any Investor is a member shall be aggregated, and deemed Beneficially Owned and held by each
Investor, for purposes of this Section 3.2(a)(i));

               (ii) (A) make or in any way participate in any “solicitation” of “proxies” (as such terms are
used in the rules and regulations of the SEC) with respect to any Voting Stock, or (B) seek to
advise or influence any Person with respect to the voting of any Voting Stock (other than (x) the
Investor or any Affiliate or (y) in accordance with and consistent with the recommendation of the
Board);

               (iii) deposit any Voting Stock or Series B Shares in a voting trust or, except as otherwise
provided or contemplated herein, subject any Voting Stock or Series B Shares to any arrangement or
agreement with any Person (other than between the Investor and any of its First Tier Affiliates)
with respect to the voting of such Voting Stock or Series B Shares;

               (iv) join a 13D Group (other than a group comprising solely of the Investor and its Permitted
Transferees) or other group, or otherwise act in concert with any third Person for the purpose of
acquiring, holding, voting or disposing of Voting Stock, Series B Shares or Convertible Securities;

               (v) effect or seek, offer or propose (whether publicly or otherwise) to effect any Change of
Control or any acquisition of Equity Securities in excess of the Standstill Limit;

15

 

               (vi) otherwise act, alone or in concert with others, to effect or seek, offer or propose
(whether publicly or otherwise) to effect control of the management, Board or policies of the
Company; or

               (vii) otherwise take any action that would or could reasonably be expected to compel the
Company to make a public announcement (including any disclosure required to be made in any SEC
filing under the rules and regulations of the SEC) regarding any of the matters set forth in this
Section 3.2(a).

     Notwithstanding the foregoing, the restrictions contained in this Section 3.2(a) shall not (A)
apply with respect to the election of the Series B Directors by Investor and its Permitted
Transferees in accordance with the Certificate of Designation, (B) prevent, restrict, encumber or
in any way limit the ability of any Series B Director to vote on matters, make non-public
statements to officers, employees, agents, management or other Directors or to take any action or
make any statement at any meeting of the Board or any committee or subcommittee thereof in his or
her capacity as a Director, (C) apply to or restrict any non-public discussions or other non-public
communications between or among directors, members, officers, employees or agents of the Investor
or any First Tier Affiliate of the Investor, or (D) restrict any disclosure or statements required
to be made by any Series B Director or the Investor under applicable law.

          (b) If during the Standstill Period the Investor is entitled (as a result of dilution due to
future share issuances by the Company) to purchase shares of Common Stock (up to the Standstill
Limit) in compliance with this Section 3.2, then unless the Board otherwise approves such purchases
shall be made in full compliance with all applicable securities laws, but shall not be made by
means of any tender offer.

          (c) The restrictions set forth in Section 3.2(a) shall terminate if, at any time during the
Standstill Period, (i) the Company publicly announces its entry into a definitive agreement, the
consummation of which would result in a Change of Control, and such agreement has not been approved
by a majority of the Series B Directors, (ii) the Company shall have waived the terms of its Rights
Agreement to permit any Person (other than the Investor or any 13D Group of which the Investor is a
member) to effect a Change of Control or otherwise acquire more than fifteen percent (15%) of the
outstanding Common Stock, and such transaction has not been approved by a majority of the Series B
Directors, or (iii) any Person (other than the Investor or any Affiliate of the Investor or any 13D
Group of which the Investor or any Affiliate of the Investor is a member) shall have commenced a
bona fide public tender or exchange offer which if consummated would result in a Change of Control,
unless the Board recommends against such tender or exchange offer within ten (10) Business Days
after the commencement (as such term is defined in Rule 14d-2 under the Exchange Act) thereof and
thereafter continues to oppose such tender or exchange offer. If (x) the restrictions set forth in
Section 3.2(a) shall have terminated as provided in this Section 3.2(c), and (y) any definitive
agreement described in clause (i) above, or transaction described in clause (ii) above, or tender
or exchange offer described in clause (iii) above, as the case may be, shall have been terminated
or abandoned prior to consummation thereof, and (z) any alternative offer or proposal by Investor
in response to any such agreement, transaction, tender offer or exchange offer shall also have been
abandoned or withdrawn prior to consummation thereof, then the restrictions set forth in Section
3.2(a) shall be reinstated.

16

 

          (d) If during the Standstill Period the Board elects to commence a process intended to lead to
a proposal with respect to Change of Control of the Company (whether in response to a proposal from
a third party or otherwise), the Company will notify the Investor of the Board’s election and will
permit the Investor to participate in such process as a potential bidder, if the Investor so
elects, on the same terms and conditions as third party participants. As a condition to the
Investor’s participation in such process, the Board may require that the Investor agree in writing
with the Company that if such process results in the Board’s approval of a Change of Control
transaction with a Person other than the Investor that is a Superior
Proposal as compared to any bona fide written proposal from the Investor, then the Investor
will consent to such transaction, will raise no objection to the consummation thereof, and will
tender shares of Equity Securities Beneficially Owned by it, as applicable, upon the consummation
of such transaction. In the event that any such transaction requires the approval of the Company’s
stockholders, the Investor agrees, if the matter is brought to a vote at a stockholder meeting,
that the Investor will be present, in person or by proxy, as holders of Voting Stock, at all such
meetings and be counted for determining the presence of a quorum at such meetings and will vote for
the approval of any such transaction approved and recommended by the Board. So long as the Board
continues to recommend such transaction, the Investor agrees to vote and to use reasonable efforts
to cause its Affiliates, as the case may be, to vote all shares of Voting Stock Beneficially Owned
by the Investor and its Affiliates in favor of such transaction and for the approval of the terms
thereof and in opposition to any and all other proposals that are intended, or could reasonably be
expected to delay, prevent, impair, interfere with, postpone or adversely affect the ability of the
Company to consummate the proposals that are approved and recommended by the Board.

     Section 3.3 Other Share Acquisitions. Following the expiration of the Standstill Period, if
the Investor and its Affiliates desire to acquire Beneficial Ownership of Equity Securities that
would cause the aggregate Beneficial Ownership of the Investor and its Affiliates to exceed (a)
seventy percent (70%) of the number of shares of Common Stock outstanding , if prior to such
proposed acquisition the Beneficial Ownership of the Investor and its Affiliates is at least forty
percent (40%) of the number of shares of Common Stock outstanding, or (b) fifty percent (50%) of
the number of shares of Common Stock outstanding , if prior to such proposed acquisition the
Beneficial Ownership of the Investor and its Affiliates is less than forty percent (40%) of the
number of shares of Common Stock outstanding, such acquisition may be made only pursuant to a
tender offer, exchange offer, merger or other business combination involving the offer to acquire
100% of the Common Stock not owned by the Investor and its Affiliates which in the case of any such
transaction to be effected by means of a tender or exchange offer, includes a commitment by the
Investor or such Affiliate to promptly consummate a merger (which may be a short-form merger) to
acquire any remaining shares of Common Stock at the same price.

     Section 3.4 Section 203 of the DGCL. The Board, prior to the execution of the Share Exchange
Agreement, has taken all necessary action to ensure that the transactions contemplated by the Share
Exchange Agreement and the consummation of any of the transactions contemplated thereby (including
the execution, delivery and performance of this Agreement) will be deemed to be exceptions to the
provisions of Section 203 of the Delaware General Corporation Law (the “DGCL”), including the
approval of any transaction contemplated thereby that results in any “affiliate” or “associate” (as
each such term is defined in Section 203 of the

17

 

DGCL) of the Investor becoming an “interested
stockholder” (as defined in Section 203 of the DGCL) by virtue of the Investor or its “affiliates”
or “associates” owning any Common Stock acquired pursuant to the Share Exchange Agreement or after
the Closing pursuant to Section 3.1 of this Agreement. Accordingly, the ownership by the Investor,
its “affiliates” and its “associates” of Common Stock acquired pursuant to the Share Exchange
Agreement or after the Closing pursuant to Section 3.1 of this Agreement will not result in the
provisions of Section 203 of the DGCL applicable to a “business combination” (as defined in Section
203 of the DGCL) to apply between such persons (or their “affiliates” or “associates”) and the
Company.

     Section 3.5 Rights Agreement. The Board, prior to the execution of the Share Exchange
Agreement, has taken all necessary action to render the Rights Agreement inapplicable to the
transactions contemplated by the Share Exchange Agreement and the consummation of any of the
transactions contemplated thereby (including the execution, delivery and performance of this
Agreement).

ARTICLE 4

REGISTRATION RIGHTS

     Section 4.1 Demand Registrations.

          (a) Requests for Registration. After the expiration of the Lock-up Period and subject
to the terms, conditions and limitations of this Article 4, the holders of twenty-five percent
(25%) or more of the Investor Registrable Securities then outstanding may request that the Company
effect a registration for a Public Offering in the United States of all or any portion of the
Investor Registrable Securities; provided that the Investor Registrable Securities to be included
in such registration shall (i) have a market value on the date such request for registration is
received of at least $25 million based on the closing price of the Common Stock on the trading day
immediately preceding the day on which such request is delivered, or (ii) represent at least six
percent (6%) of the total shares of Common Stock then outstanding, or (iii) represent all Investor
Registrable Securities then outstanding. All registrations requested as described in and meeting
the requirements of this Section 4.1 are referred to herein as “Demand Registrations.” Each
request for a Demand Registration shall specify the approximate number of Registrable Securities
requested to be registered. Subject to Section 4.1(c) below, any such Demand Registration may
include registration of shares on a “shelf” Registration Statement pursuant to Rule 415 under the
Securities Act. Promptly after receipt of any such request pursuant to this Section 4.1, the
Company shall give written notice of such requested registration to all other holders of
Registrable Securities and, subject to the terms of this Agreement, shall include in such
registration all Registrable Securities with respect to which the Company has received written
requests indicating the holder of such Registrable Securities and the number of Registrable
Securities that such holder elects to include in such registration within twenty (20) days after
the receipt of the Company’s notice.

          (b) Priority on Demand Registrations. If a Demand Registration is an Underwritten
Offering and the managing underwriters, which shall be one (1) or more nationally recognized
investment banks selected by the Company and reasonably acceptable to the holders

18

 

of a majority of
the Investor Registrable Securities to be included in such Demand Registration, advise the Company
in writing that they have determined in good faith that the number of Registrable Securities and,
if permitted hereunder, other securities requested to be included in such offering exceeds the
number of Registrable Securities and other securities, if any, which can be sold therein without
adversely affecting the marketability of the offering or the trading price of the Common Stock, the
Company shall include in such registration (i) first, the quantity of Investor Registrable
Securities requested to be included in such Demand Registration, pro rata among the respective
holders thereof on the basis of the number of Investor Registrable Securities requested to be
included in such registration by each such holder, (ii) second,
securities to be sold by the Company for its own account, to the extent that in the opinion
of such underwriters such securities can be sold without adversely affecting the marketability of
the offering or the trading price of the Common Stock, (iii) third, other Registrable Securities
requested to be included in such registration, which in the opinion of such underwriters can be
sold without adversely affecting the marketability of the offering or the trading price of the
Common Stock, pro rata among the respective holders thereof on the basis of the number of shares
requested to be included in such registration, and (iv) fourth, other securities requested to be
included in such registration, which in the opinion of such underwriters can be sold without
adversely affecting the marketability of the offering or the trading price of the Common Stock, pro
rata among the respective holders thereof on the basis of the number of shares requested to be
included in such registration by each such holder. Any Persons other than holders of Registrable
Securities who participate in Demand Registrations which are not at the Company’s or its
Subsidiaries’ expense must pay their share of the Registration Expenses.

          (c) Restrictions on Demand Registrations. Notwithstanding anything to the contrary in
this Section 4.1:

               (i) The Company shall not be obligated (A) to effect more than two (2) Demand Registrations in
any period of fifteen (15) months, (B) any Demand Registration within one hundred thirty-five (135)
days after the effective date of a previous Demand Registration or a previous registration in which
the holders of Registrable Securities were given piggyback rights pursuant to Section 4.2 hereof
(in which the number of Investor Registrable Securities requested to be included in such Piggyback
Registration were not reduced by more than 50% pursuant to Section 4.2(b) or (c) hereof) or (C) to
have more than one (1) “shelf” Registration Statement pursuant to Rule 415 effective under the
Securities Act at any time (other than shelf registrations filed pursuant to Rule 429 under the
Securities Act).

               (ii) A Demand Registration will not be deemed to have been effected for purposes of this
Section 4.1 unless the Registration Statement relating thereto (A) has become effective under the
Securities Act, (B) has remained effective for a period of at least sixty (60) days (or such
shorter period in which all Registrable Securities of the holders included in such registration
have actually been sold thereunder), and (C) at least seventy-five percent (75%) of the Registrable
Securities requested to be included in such Demand Registration by the holders of the Investor
Registrable Securities are so included.

               (iii) If the majority of the Company Nominated Directors determines in good faith that the
filing or effectiveness of a Registration Statement in connection with any requested Demand
Registration (A) would be reasonably likely to interfere with any pending or

19

 

contemplated
acquisition, divestiture, financing, registered primary offering or other transaction involving the
Company or (B) would require disclosure of facts or circumstances and which the Company would not
otherwise be required to then disclose, which disclosure would, in the good faith judgment of the
Board, be disadvantageous to the Company, or (C) would otherwise be materially detrimental to the
Company, then the Company may delay (or if necessary or advisable withdraw) the filing, or delay
the effectiveness, of such registration (or offers and sales of securities registered under a shelf
Demand Registration) for a period of up to one hundred twenty (120) days so long as the basis for
such delay continues (it being agreed that the Company may not apply the provisions of this clause
(iii) to delay requested registrations for an
aggregate period of more than one hundred eighty (180) days in any twelve (12)-month period).

               (iv) In order to delay the filing of a Registration Statement pursuant to Section 4.1(c)(iii),
the Company shall promptly (but in any event within ten (10) calendar days) upon determining to
make such deferral, deliver to each holder requesting such Demand Registration a certificate of an
authorized officer stating that the Company is delaying such filing pursuant to Section 4.1(c)(iii)
and an approximation of the anticipated delay. Within twenty (20) calendar days after receiving
such certificate, the holders of a majority of the Investor Registrable Securities participating in
such offering may withdraw their request for a Demand Registration by giving written notice to the
Company, and if withdrawn, the request for Demand Registration shall be deemed not to have been
made for all purposes of this Agreement. In the event the Company delays or suspends the sale of
securities registered under a shelf Demand Registration pursuant to Section 4.1(c)(iii), then the
required period of effectiveness set forth in Section 4.1(c)(ii)(B) shall be extended by the number
of days of such delay or suspension that occurred during the effectiveness of such Registration
Statement.

          (d) Demand Withdrawal. Any holder of Registrable Securities that has requested its
Registrable Securities be included in a Demand Registration pursuant to Section 4.1(a) may withdraw
all or any portion of its Registrable Securities included in a Demand Registration from a Demand
Registration at any time prior to the effectiveness of the applicable Registration Statement. Upon
receipt of a notice to such effect from holders of Registrable Securities with respect to all of
the Registrable Securities included in such Demand Registration, the Company shall cease all
efforts to secure effectiveness of the applicable Demand Registration Statement and such
registration nonetheless shall be deemed a Demand Registration for purposes of Section 4.1(c)
unless the withdrawal is made (i) following the occurrence of a Material Adverse Change or (ii)
after a delay of more than ninety (90) days in the effectiveness of the registration statement from
the date on which the Demand Registration was requested.

          (e) Underwritings. In the case of any Demand Registration that is an Underwritten
Registration, the managing underwriters shall be selected by the Company and shall be reasonably
acceptable to the Investor. No holder of Registrable Securities may participate or have any of
such holder’s Registrable Securities included in such Underwritten Registration unless such holder
accepts the terms of such underwriting as approved by the Company and enters into such
underwriting, custody, indemnity and other agreements, each in customary form and containing such
representations, warranties and other provisions as are customarily made by selling stockholders in
connection with similar Underwritten Registrations, and completes and delivers such questionnaires
and other documents as reasonably requested by the managing underwriters of such Underwritten
Offering.

20

 

     Section 4.2 Piggyback Registrations.

          (a) Right to Piggyback. Following the expiration of the Lock-up Period, whenever the
Company proposes to register any of its securities (other than pursuant to a Demand Registration or
any registration effected pursuant to Form S-4, S-8 or any successor forms and other than a
registration relating solely to the sale of securities to participants in a Company plan, a
registration relating to a reorganization of the Company or other transaction under Rule 145 of the
Securities Act, or a registration on any form that does not include
substantially the same information as would be required to be included in a Registration
Statement covering the sale of Registrable Securities) and the registration form to be used may be
used for the registration of Registrable Securities (a “Piggyback Registration”), the Company shall
give prompt written notice (but in no event less than twenty (20) calendar days prior to the
proposed filing of such Registration Statement) to all holders of Registrable Securities of its
intention to effect such a registration, setting forth (to the extent then known) the principal
terms and conditions of such issuance, including the anticipated proposed offering price (or range
of offering prices), the anticipated date of the filing of the Registration Statement and the
number and type of securities to be registered, and shall, subject to the other provisions of this
Section 4.2, include in such registration all Registrable Securities with respect to which the
Company has received written requests for inclusion therein within ten (10) calendar days after the
receipt of the Company’s notice. No registration of Registrable Securities effected under this
Section 4.2 will relieve the Company of any of its obligations to effect registrations of Investor
Registrable Securities pursuant to Section 4.1 hereof. The election by any holder of Registrable
Securities not to exercise its rights to have any or all of its Registrable Securities registered
pursuant to this Section 4.2 shall not affect its rights as to future issuances.

          (b) Priority on Primary Registrations. If a Piggyback Registration is a primary
Underwritten Registration on behalf of the Company, and the managing underwriters advise the
Company in writing that they have determined in good faith that the number of securities requested
to be included in such registration exceeds the number which can be sold in such offering without
adversely affecting the marketability of the offering, the Company shall include, subject to
Section 4.2(d), in such registration (i) first, the securities the Company proposes to sell, (ii)
second, Registrable Securities requested to be included in such registration, pro rata among the
respective holders thereof on the basis of the number of shares requested to be included in such
registration by each such holder and (iii) third, at the discretion of the Company, other
securities of the Company requested to be included in such registration, pro rata among the
respective holders thereof on the basis of the number of shares requested to be included in such
registration by each such holder.

          (c) Priority on Secondary Registrations. If a Piggyback Registration is an secondary
Underwritten Registration on behalf of holders of the Company’s securities who have the contractual
right to initiate such a registration (including pursuant to a Demand Registration), and the
managing underwriters advise the Company in writing that they have determined in good faith that
the number of securities requested to be included in such registration exceeds the number which can
be sold in such offering without adversely affecting the marketability of the offering, the Company
shall include, subject to the other provisions of this Section 4.2, in such registration, (i)
first, the securities requested to be included therein by the holders initially requesting such
registration, pro rata among the respective holders thereof on the basis of the

21

 

number of shares
requested to be included in such registration by each such holder, and (ii) second, any Registrable
Securities requested (including under this Section 4.2) to be included therein, pro rata among the
respective holders thereof on the basis of the number of shares owned by each such holder.

          (d) Withdrawal. Any holder of Registrable Securities shall have the right to withdraw
all or part of its request for inclusion of its Registrable Securities in a Piggyback Registration
at any time prior to later of (1) the filing of the applicable Registration Statement, or
(2) five (5) Business Days prior to the effectiveness of the applicable Registration
Statement, in each case by giving written notice to the Company of its request to withdraw. The
Company shall have the right to terminate or withdraw any registration initiated by it under this
Section 4.2 prior to the effectiveness of the applicable Registration Statement whether or not any
holder of Registrable Securities has elected to include securities in such Registration Statement.

          (e) Certain Conditions. If any Piggyback Registration is an Underwritten
Registration, no holder of Registrable Securities may participate or have any of such holder’s
Registrable Securities included in such Underwritten Registration unless such holder accepts the
terms of such underwriting as approved by the Company and enters into such underwriting, custody,
indemnity and other agreements, each in customary form and containing such representations,
warranties and other provisions as are customarily entered into by selling stockholders in
connection with similar Underwritten Registrations, and completes and delivers such questionnaires
and other documents as reasonably requested by the managing underwriters of such Underwritten
Offering. No holders of Registrable Securities shall have any right to participate in or approve
the selection of the underwriters for an offering described in this Section 4.2.

     Section 4.3 Holdback Agreements.

          (a) Holders of Registrable Securities. Notwithstanding anything contained herein to
the contrary and to the extent not inconsistent with applicable law, each holder of Registrable
Securities shall not effect any public sale or distribution (including sales pursuant to Rule 144
under the Securities Act, but excluding, to the extent permitted by the underwriter managing the
registered public offering, sales effected to pay the exercise price of a stock option pursuant to
any broker-assisted exercise or “cashless” exercise of such stock option) of Equity Securities,
enter into a transaction which would have the same effect, or enter into any swap, hedge or other
arrangement that transfers, in whole or in part, any economic consequences of ownership of such
securities, whether any such aforementioned transaction is to be settled by delivery of such
securities or other securities, in cash or otherwise, or publicly disclose the intention to make
any such offer, sale, pledge or disposition, or to enter into any such transaction, swap, hedge or
other arrangement, in each case during the ten (10) days prior to and the ninety (90) days after
the effective time of any (x) underwritten Demand Registration (except as part of such Underwritten
Registration) or (y) underwritten Piggyback Registration in which any of such holder’s Registrable
Securities are included (except as part of such Underwritten Registration) (a “Stand-off Period”),
except as otherwise agreed to by the underwriter managing the Underwritten Registration. If (i)
the Company issues an earnings release or other material news or a material event relating to the
Company and its Subsidiaries during the last seventeen (17) days of the Stand-off Period or (ii)
prior to the expiration of the Stand-off Period, the Company

22

 

announces that it will release earnings results during the sixteen (16)-day period
beginning upon the expiration of the Stand-off Period, then to the extent necessary for a managing
or co-managing underwriter of a registered offering required hereunder to comply with NASD Rule
2711(f)(4), the Stand-off Period shall be extended until eighteen (18) days after the earnings
release or the occurrence of the material news or event, as the case may be.

          (b) The Company. The Company shall agree to such limitation on its public sale or
distribution of its Equity Securities as may be reasonably requested by the managing underwriters
in connection with any Underwritten Registration; provided, that such limitations shall not
continue beyond the one hundred thirty-fifth (135th) day after the effective date of the
Registration Statement in question.

     Section 4.4 Registration Procedures.

          (a) Whenever the holders of Investor Registrable Securities have requested that any Investor
Registrable Securities be registered pursuant to Section 4.1, the Company shall use its reasonable
best efforts to effect the registration and the sale of such Investor Registrable Securities in
accordance with the intended method of disposition thereof, and pursuant thereto the Company shall
as promptly as reasonably practicable (unless waived by the holders of a majority of Investor
Registrable Securities participating in such):

               (i) prepare the required Registration Statement including all exhibits and financial
statements required under the Securities Act to be filed therewith, and before filing a
Registration Statement, prospectus or any issuer free writing prospectus, or any amendments or
supplements thereto, (x) furnish to the underwriters, if any, and to the selling holders, copies of
all documents prepared to be filed, and to consider in good faith and discuss with such
underwriters, selling holders and counsel, any comments thereon by such underwriters, selling
holders and counsel and (y) not file any Registration Statement, prospectus or any amendments or
supplements thereto to which the holders of fifty percent (50%) of the Investor Registrable
Securities or the underwriters, if any, shall reasonably object (other any amendments or
supplements that, in the good faith judgment of the Company, are required to correct any
misstatement or omission of a material fact, or make any statement in any such Registration
Statement or prospectus not misleading, or are otherwise required to comply with applicable law,
rules or regulations);

               (ii) file with the SEC, a Registration Statement with respect to such Registrable Securities
and use its reasonable best efforts to cause such Registration Statement to become effective and to
remain effective until the earlier of eighteen (18) months (in the case of a shelf Demand
Registration Statement) or sixty (60) days (in the case of any other Demand Registration Statement)
from the effective time of such Registration Statement or such earlier time as the Registrable
Securities covered by such Registration Statement have been sold in accordance with the intended
method of distribution therefore; and

               (iii) prepare and file with the SEC such supplements and amendments to such Registration
Statement as may be required to keep such Registration Statement effective for the period of time
provided in Section 4.4(a)(ii) above.

23

 

          (b) With respect to each Registration Statement that includes Registrable Securities (unless
waived by the holders of a majority of Registrable Securities participating in such), the Company
shall:

               (i) notify the selling holders and the managing underwriters, if any, and (if requested)
confirm such advice in writing, as soon as practicable after notice thereof is received by the
Company (a) when the Registration Statement or any amendment thereto has been filed or becomes
effective or the prospectus or any amendment or supplement to the prospectus has been filed, (b) of
any written comments or requests by the SEC or any other federal, state or regulatory authority for
amendments or supplements to the Registration Statement (or the related prospectus), (c) of the
issuance by the SEC of any stop order or cease trade order suspending the effectiveness of the
Registration Statement or any order preventing or suspending the use of any preliminary prospectus
or prospectus, or the initiation or threatening of any proceedings for such purposes, (c) of the
receipt by the Company of any notification with respect to the suspension of the qualification of
the Registrable Securities for offering or sale in any jurisdiction or the initiation or
threatening of any proceeding for such purpose, and (d) if, at any time, the representations and
warranties of the Company in any applicable underwriting agreement cease to be true and correct in
all material respects;

               (ii) furnish to each selling holder and each managing underwriter, without charge, one (1)
copy of the Registration Statement and any post-effective amendment or supplement thereto,
including without limitation financial statements and schedules, all documents incorporated therein
by reference and all exhibits (including without limitation those incorporated by reference);

               (iii) deliver to each selling holder and each underwriter, if any, without charge, as many
copies of the applicable prospectus (including each preliminary prospectus) and any amendment or
supplement thereto, and such other documents as such selling holder or underwriter may reasonably
request in order to facilitate the disposition of the Registrable Securities by such selling holder
or underwriter, it being understood that the Company consents (subject to the provisions of Section
4.4(b)(v) below) to the use of such prospectus or any amendment or supplement thereto by such
selling holder and the underwriters, if any, in connection with the offering and sale of the
Registrable Securities covered by such prospectus or any amendment or supplement thereto;

               (iv) use its reasonable best efforts to register or qualify such Registrable Securities under
such other securities or blue sky laws of such jurisdictions as the managing underwriter of any
Underwritten Registration reasonably requests; provided, that the Company shall not be required to
(i) qualify generally to do business in any jurisdiction where it would not otherwise be required
to qualify but for this subsection, (ii) subject itself to taxation in any such jurisdiction or
(iii) consent to general service of process in any such jurisdiction;

               (v) promptly notify the selling holders and the managing underwriters, if any, at any time
during the period of effectiveness set forth in Section 4.4(a) above, when the Company becomes
aware of the happening of any event as a result of which the prospectus included in such
Registration Statement (as then in effect) contains any untrue statement of a material fact or
omits to state a material fact necessary to make the statements therein when such

24

 

prospectus was delivered not misleading in light of the circumstances then existing or, if for
any other reason it shall be necessary during such time period to amend or supplement the
prospectus in order to comply with the Securities Act, as promptly as practicable thereafter,
prepare and file with the SEC, a supplement or amendment to such prospectus, which will correct
such statement or omission or effect such compliance. Each holder agrees that, upon receipt of any
notice from the Company of the happening of any event of the kind described in this Section
4.4(b)(v) such holder will forthwith discontinue disposition of Registrable Securities pursuant to
such Registration Statement until such holder’s receipt of the copies of the supplemented or
amended prospectus contemplated by this Section 4.4(b)(v) or until it is advised in writing by the
Company that the use of the prospectus may be resumed, and has received copies of any additional or
supplemental filings which are incorporated by reference in the prospectus and, if so directed by
the Company, such holder will deliver to the Company (at the Company’s expense) all copies, other
than permanent file copies then in such holder’s possession, of the prospectus, covering such
Registrable Securities current at the time of receipt of such notice;

               (vi) use its reasonable best efforts to prevent, or obtain the withdrawal of, any stop order
or other order or notice preventing or suspending the use of any preliminary or final prospectus or
any issuer free writing prospectus;

               (vii) promptly incorporate in a prospectus supplement or post-effective amendment such
information as the managing underwriter or underwriters reasonably determines should be included
therein relating to the plan of distribution with respect to such Registrable Securities; and make
all required filings of such prospectus supplement or post-effective amendment as soon as
reasonably practicable after being notified of the matters to be incorporated in such prospectus
supplement or post-effective amendment;

               (viii) cause all Registrable Securities covered by the Registration Statement to be listed on
each securities exchange or automated quotation system on which similar securities issued by the
Company are then listed or quoted;

               (ix) provide a transfer agent and registrar and, if applicable, a CUSIP number for all such
Registrable Securities not later than the effective date of the first Registration Statement
relating to Registrable Securities or securities of any class of the Company;

               (x) cooperate with the selling holders and the managing underwriter or underwriters, if any,
to facilitate the timely preparation and delivery of certificates representing Registrable
Securities to be sold and not bearing any restrictive legends; and enable such Registrable
Securities to be in such denominations and registered in such names as the managing underwriters
may request; and

               (xi) if the Registration Statement is an Underwritten Registration, enter into an underwriting
agreement with the underwriters in customary form and containing such representations, warranties
and other provisions as are customarily made by issuers in connection with similar Underwritten
Registrations.

25

 

          (c) It shall be a condition precedent to the obligations of the Company to take
any action pursuant to Section 4.1 or 4.2 that each seller of Registrable Securities as to
which any registration is being effected shall furnish to the Company such information regarding
such seller, the Registrable Securities held by such seller, and the intended method of disposition
of such securities as shall be required to timely effect the registration of such seller’s
Registrable Securities.

          (d) If, at any time at a shelf registration under Rule 415 under the Securities Act and under
which Investor Registrable Securities have been registered is in effect, the Company shall furnish
to the Investor a certificate of an authorized officer stating that the continued use of such shelf
Registration Statement would require the Company to make an Adverse Disclosure, then the Company
may suspend the use by the Investor of such Registration Statement for period of up to ninety (90)
days (a “Shelf Suspension”); provided however, that the Company shall not be permitted to exercise
a Shelf Suspension more than twice in any twelve (12)-month period for each Registration Statement.
In the case of a Shelf Suspension, the Investor agrees to suspend use of the applicable prospectus.
The Company shall promptly notify the Investor of the termination of any Shelf Suspension, and
shall promptly amend or supplement the prospectus, if necessary, so it does not contain any untrue
statement or omission and furnish to the Investor such numbers of copies of the amended or
supplemented prospectus as it may reasonably request. The Company agrees, if necessary, to
supplement or amend the Registration Statement, if required by the Securities Act or the rules or
regulations promulgated thereunder. In the event the Company exercises a Shelf Suspension, then
the required period of effectiveness set forth in Section 4.1(c)(ii)(B) shall be extended by the
number of days of such Shelf Suspension that occurred during the effectiveness of such Registration
Statement. As used herein, “Adverse Disclosure” means public disclosure of material non-public
information that, in the good faith judgment of the Company Nominated Directors, (i) would be
required to be made in any report or Registration Statement filed with the SEC by the Company so
that such report or Registration Statement would not be materially misleading; (ii) would not be
required to be made at such time but for the filing, effectiveness or continued use of such report
or Registration Statement, and (iii) the Company has a bona fide business purpose for not
disclosing publicly.

          (e) No holder of Investor Registrable Securities shall have any right to obtain or seek an
injunction restraining or otherwise delaying any registration as a result of any controversy that
might arise with respect to the interpretation or implementation of any provision of this
Agreement.

     Section 4.5 Registration Expenses.

          (a) All expenses incident to the Company’s performance of or compliance with this Agreement,
including all registration and filing fees, fees and expenses of compliance with securities or blue
sky laws, printing expenses, messenger and delivery expenses, fees and disbursements of custodians,
and fees and disbursements of counsel for the Company and all independent certified public
accountants, underwriters (excluding discounts and commissions and taxes imposed with respect to
Registrable Securities on the sale and transfer thereof) and other Persons retained by the Company
(all such expenses being herein called “Registration Expenses”), shall be borne by the Company, and
the Company shall pay its internal expenses

26

 

(including all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit or quarterly review, the expense of any liability
insurance and the expenses and fees for listing the securities to be registered on the Exchange.

          (b) All other Registration Expenses to the extent not expressly reimbursed in this Section
4.5, shall be borne by all of the sellers of securities included in such registration in proportion
to the aggregate selling price of the securities to be so registered (it being understood that all
fees and expenses (including with respect to any fees and expenses of counsel and other advisors)
of any holder of Registrable Securities shall be borne by such holder).

     Section 4.6 Indemnification.

          (a) The Company agrees to indemnify and hold harmless, to the full extent permitted by law,
each holder of Registrable Securities, such holder’s officers, directors, stockholders, members,
partners, agents, advisors, representatives and employees, and each Person who controls such holder
(within the meaning of the Securities Act) against all losses, claims, damages, liabilities,
judgments, costs (including reasonable and documented costs of investigation) and expenses
(including reasonable attorney’s fees) arising out of or based upon, any untrue or alleged untrue
statement of a material fact contained in any Registration Statement, prospectus or preliminary
prospectus with respect to such Registrable Securities or any amendment thereof or supplement
thereto, or any document incorporated by reference therein or any omission in any application or
other document or communication executed by or on behalf of the Company filed in any jurisdiction
in order to qualify any securities covered by such Registration Statement under the “blue sky” or
securities laws thereof, or any omission or alleged omission of a material fact required to be
stated therein or necessary to make the statements therein not misleading, provided, that the
Company shall not be obligated to indemnify any holder of Registrable Securities (or any officer,
director or controlling Person of such holder) to the extent that any such loss, claim, damage,
liability, judgment, cost or expense arises out of or is based upon an untrue statement or alleged
untrue statement or omission or alleged omission made in reliance on and in conformity with written
information furnished to the Company by such holder expressly for use therein.

          (b) In connection with any Registration Statement in which a holder of Registrable Securities
is participating, each such holder shall furnish to the Company in writing such information and
affidavits as the Company reasonably requests for use in connection with any such Registration
Statement or prospectus and, to the extent permitted by law, shall indemnify the Company, its
Directors and officers and each Person who controls the Company (within the meaning of the
Securities Act), any underwriter and each other holder of Registrable Securities participating in
the offering contemplated by such Registration Statement against any losses, claims, damages,
liabilities, judgments, costs (including reasonable and documented costs of investigation) and
expenses (including reasonable attorney’s fees) arising out of or based upon any untrue or alleged
untrue statement of material fact contained in the Registration Statement, prospectus or
preliminary prospectus or any amendment thereof or supplement thereto or any omission or alleged
omission of a material fact required to be stated therein or necessary to make the statements
therein not misleading, to the extent (but only to the extent) that such untrue statement or
omission is made in reliance on and in conformity with any written information furnished to the
Company by such holder or its agents expressly for use therein; provided that

27

 

such obligation to indemnify shall be individual, not joint and several, for each holder and shall
be limited to the net amount of proceeds received by such holder from the sale of Registrable
Securities pursuant to such Registration Statement. Such indemnity shall remain in full force and
effect regardless of any investigation made by or on behalf of such holder or any indemnified party
and shall survive the transfer of such Registrable Securities by such holder.

          (c) Any Person entitled to indemnification hereunder shall (i) give prompt written notice to
the indemnifying party of any claim with respect to which it seeks indemnification or the
commencement of any action or proceeding for which the indemnified party intends to claim
indemnification or contribution pursuant to this Agreement and (ii) permit such indemnifying party
to participate in such claim, action or proceeding and, to the extent it may wish to assume the
defense at its own expense of such claim with counsel reasonably satisfactory to the indemnified
party, permit such indemnifying party to assume such defense; provided, that any Person entitled to
indemnification hereunder shall have the right to select and employ separate counsel and to
participate in the defense of such claim, which fees and expenses of such separate counsel shall be
at the expense of the indemnified party unless (A) the indemnifying party has agreed in writing to
pay such fees or expenses, (B) the indemnifying party shall have elected not to, or shall have
failed to assume the defense of such claim within a reasonable time after receipt of notice of such
claim from the indemnified party and employ counsel reasonably satisfactory to such indemnified
party, (C) there may be legal defenses available to it or other indemnified parties that are
different from or in addition to those available to the indemnifying party, or (D) the indemnified
shall have been advised by counsel that a conflict of interest may exist between such Person and
the indemnifying party with respect to such claims (in which case, if the indemnified party
notifies the indemnifying party in writing that such indemnified party elects to employ separate
counsel at the expense of the indemnifying party, the indemnifying party shall not have the right
to assume the defense of such claim on behalf of such Person). In no event shall an indemnifying
party be responsible, in any one action or separate but similar actions arising out of the same
general allegations, for the fees and expenses of more than one separate counsel (plus one local
counsel, if reasonably required) for all indemnified parties. The failure to deliver written
notice to the indemnifying party within a reasonable time of the commencement of any such action,
suit, proceeding or investigation shall not relieve such indemnifying party of any liability to the
indemnified party under this Section 4.6 except to the extent that the indemnifying party is
actually prejudiced thereby. The omission of an indemnified party to deliver written notice to the
indemnifying party will not relieve such indemnifying party of any liability that it may have to
any indemnified party otherwise than under this Section 4.6.

          (d) If the indemnification provided for in this Section 4.6 from the indemnifying party is
applicable by its terms but is unavailable to a party that would have been entitled to
indemnification pursuant to the provisions of this Section 4.6 or insufficient in respect of any
losses, claims, damages, liabilities, judgments, costs (including reasonable and documented costs
of investigation) and expenses (including reasonable attorney’s fees) referred to herein, then the
indemnifying party, in lieu of indemnifying such indemnified party, shall contribute to the amount
paid or payable by such indemnified party as a result of such losses, claims, damages, liabilities,
judgments, costs (including reasonable and documented costs of investigation) and expenses
(including reasonable attorney’s fees) in such proportion as is appropriate to reflect the relative
fault of the indemnifying party and indemnified parties in

28

 

connection with the actions which resulted in such losses, claims, damages, liabilities,
judgments, costs (including reasonable and documented costs of investigation) and expenses
(including reasonable attorney’s fees), as well as other relevant equitable considerations. The
relative fault of such indemnifying party and indemnified parties shall be determined by reference
to, among other things, whether any action in question, including any untrue or alleged untrue
statement of a material fact or omission or alleged omission to state a material fact, has been
made by, or relates to information supplied by, such indemnifying party or indemnified parties, and
the parties’ relative intent, knowledge, access to information and opportunity to correct or
prevent such action. The amount paid or payable by a party as a result of losses, claims, damages,
liabilities, judgments, costs (including reasonable and documented costs of investigation) and
expenses (including reasonable attorney’s fees) referred to above shall be deemed to include any
legal or other fees or expenses reasonably incurred by such party in connection with any
investigation or proceeding. The parties hereto agree that it would not be just or equitable if
contribution pursuant to this Section 4.6(d) were determined by pro rata allocation or by any other
method of allocation that does not take account of the equitable considerations referred to in this
Section 4.6(d). No Person guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty
of such fraudulent misrepresentation. Notwithstanding the provisions of this Section 4.6(d), in
connection with any Registration Statement filed by the Company, a selling holder of Registrable
Securities shall not be required to contribute any amount in excess of the net amount of proceeds
received by such holder from the sale of Registrable Securities giving rise to such contribution
obligation.

          (e) No indemnifying party shall, without the prior written consent of each indemnified party,
effect the settlement or compromise of, or consent to the entry of any judgment with respect to,
any pending or threatened action or claim in respect of which indemnification or contribution may
be sought hereunder (whether or not the indemnified party is an actual or potential party to such
action or claim) unless such settlement, compromise, or judgment (A) includes an unconditional
release of the indemnified party from all liability arising out of such action or claim without any
payment or consideration provided or obligation incurred by any indemnified party and (B) does not
include a statement as to or an admission of fault, culpability, or a failure to act, by or on
behalf of any indemnified party. No indemnification shall be available under this Agreement in
respect of any settlement of any action or claim effected by any indemnified party without the
prior written consent of the indemnifying party, which shall not be unreasonably withheld or
delayed.

          (f) The indemnification and contribution by any such party provided for under this Agreement
shall be in addition to any other rights to indemnification or contribution which any indemnified
party may have pursuant to law or contract and will remain in full force and effect regardless of
any investigation made or omitted by or on behalf of the indemnified party or any officer,
director, or controlling Person of such indemnified party and will survive the transfer of
securities.

     Section 4.7 Relation to Article 2. Nothing contained in this Article 4 shall be deemed to
affect any provision of Article 2 of this Agreement, and any sales made in Demand Registrations or
Piggyback Registrations contemplated by this Article 4 may be made only in full compliance with all
of the restrictions and limitations set forth in Article 2.

29

 

ARTICLE 5

MISCELLANEOUS

     Section 5.1 Termination. This Agreement shall terminate, except for (a) this Article 5 and
Section 4.6 (which shall survive such termination), (b) Section 1.5 (which shall survive until the
second anniversary of the date on which this Agreement otherwise terminates as provided below), (c)
Section 3.2 (which shall survive until the first anniversary of the date on which this Agreement
otherwise terminates as provided below), and (d) Section 2.1 (which shall survive until the earlier
of (A) the second anniversary of the date on which Investor and its Affiliates no longer hold
shares of Common Stock representing in the aggregate eleven percent (11%) or more of the total
outstanding shares of Common Stock or (B) such time as Investor and its Affiliates no longer hold
shares of Common Stock representing, in the aggregate, five percent (5%) or more of the total
outstanding shares of Common Stock), as follows: (i) at such time as Investor and its Affiliates
no longer hold shares of Common Stock representing in the aggregate eleven percent (11%) or more of
the total outstanding shares of Common Stock, and (ii) upon the written consent of the parties
hereto in such number and manner required for amendments hereto as provided in Section 5.7. No
termination under this Agreement will relieve any Person of liability for breach prior to such
termination.

     Section 5.2 Expenses. Except as otherwise provided herein (and except as provided in the
Share Exchange Agreement), all expenses incurred in connection with this Agreement and the
transactions contemplated hereby, including any fees and disbursements of counsel, independent
accountants and other advisors, shall be paid by the party incurring such expenses.

     Section 5.3 Successors and Assigns; Assignment. Except as otherwise expressly provided
herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors,
permitted assigns, heirs, executors and administrators of the parties hereto. Except as provided
in Section 2.1, this Agreement may not be assigned by the Investor or a Permitted Transferee
without the prior written consent of the Company. In the event of any such assignment as a result
of which more than one (1) Person shall be an Investor hereunder, all references to “the Investor”
shall be deemed to refer to all such Investors.

     Section 5.4 No Third Party Beneficiaries. This Agreement is not intended, and shall not be
deemed, to confer any rights or remedies upon any Person other than the parties hereto or otherwise
create any third-party beneficiary hereto.

     Section 5.5 Entire Agreement. This Agreement and the other agreements or documents referred
to herein, constitutes the full and entire understanding and agreement among the parties with
respect to the subject matter hereof and supersede any prior understandings, agreements or
representations by or among the parties, written or oral, that may have related to the subject
matter hereof in any way.

     Section 5.6 Severability. If any provision of this Agreement, or the application thereof,
shall for any reason and to any extent be invalid or unenforceable, then the remainder of this
Agreement and the application of such provision to other persons or circumstances shall be
interpreted so as reasonably to effect the intent of the parties hereto.

30

 

     Section 5.7 Amendment and Waiver. Any term or provision of this Agreement may be amended, and
the observance of any term of this Agreement may be waived (either generally or in a particular
instance and either retroactively or prospectively), only by a writing signed by the Company and
the Investor (or, to the extent additional Persons have joined this Agreement as Investors, by the
Investors holding a majority of the Common Shares owned by all such Investors). The waiver by a
party of any breach hereof or default in the performance hereof shall not be deemed to constitute a
waiver of any other default or any succeeding breach or default. The failure of any party to
enforce any of the provisions hereof shall not be construed to be a waiver of the right of such
party thereafter to enforce such provisions.

     Section 5.8 Notices. Except as otherwise provided herein, all notices required or permitted
hereunder shall be in writing and shall be deemed effectively given and received: (a) upon
personal hand delivery to the party to be notified; (b) when sent by confirmed facsimile if sent
during normal business hours of the recipient, if not, then on the next Business Day; or (c) one
(1) Business Day after deposit with a nationally recognized overnight courier, specifying next day
delivery, with written verification of receipt. All communications shall be sent, with respect to
the Company, the Investor and any Permitted Transferee, to their respective addresses specified in
the Share Exchange Agreement (or at such other address as any such party may specify by like
notice). The Investor will promptly provide the Company with written notice if at any time an
Investor or other Permitted Transferee no longer satisfies the criteria of a Permitted Transferee.

     Section 5.9 Interpretation. The words “hereof”, “herein” and “hereunder” and words of like
import used in this Agreement shall refer to this Agreement as a whole and not to any particular
provision of this Agreement. When reference is made in this Agreement to an Article or a Section,
such reference shall be to an Article or Section of this Agreement, unless otherwise indicated.
The table of contents, table of defined terms and headings contained in this Agreement are for
convenience of reference only and shall not affect in any way the meaning or interpretation of this
Agreement. The language used in this Agreement shall be deemed to be the language chosen by the
parties hereto to express their mutual intent, and no rule of strict construction shall be applied
against any party. Whenever the context may require, any pronouns used in this Agreement shall
include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and
pronouns shall include the plural, and vice versa. All references to agreements shall mean such
agreement as may be amended or otherwise modified from time to time. Whenever the words “include,”
“includes” or “including” are used in this Agreement, they shall be deemed to be followed by the
words “without limitation.”

     Section 5.10 Governing law.

          (a) This Agreement shall be governed in all respects by the laws of the State of Delaware.
Any disagreement, issue, dispute, claim, demand or controversy arising out of or relating to this
Agreement (each, a “Dispute”) shall be brought in the Chancery Court of Delaware, so long as such
court shall have subject matter jurisdiction over such Dispute, or if it does not have subject
matter jurisdiction over such Dispute, the United States District Court or other state court in
Delaware having jurisdiction of the Dispute. Each of the parties hereby irrevocably consents to
the jurisdiction of such courts (and of the appropriate appellate courts therefrom) in any such
Dispute and irrevocably waives, to the fullest extent permitted by law,

31

 

any objection that it may now or hereafter have to the laying of the venue of any such Dispute
in any such court and that any such Dispute which is brought in any such court has been brought in
an inconvenient forum. Process in any such Dispute may be served on any party anywhere in the
world, whether within or without the jurisdiction of any such court. Without limiting the
foregoing, each party agrees that service of process on such party as provided in Section 5.8 shall
be deemed effective service of process on such party.

          (b) TO THE FULLEST EXTENT PERMITTED BY LAW, EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY
WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH OF THE PARTIES HEREBY (A) CERTIFIES THAT
NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE,
THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER
AND (B) ACKNOWLEDGES THAT IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS
CONTEMPLATED BY THIS AGREEMENT, AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND
CERTIFICATIONS IN THIS SECTION 5.10(b).

     Section 5.11 Specific Performance; No Special Damages.

          (a) The parties hereto agree that the obligations imposed on them in this Agreement are
special, unique and of an extraordinary character, and that, in the event of breach by any party,
damages would not be an adequate remedy and each of the other parties shall be entitled to specific
performance and injunctive and other equitable relief in addition to any other remedy to which it
may be entitled, at law or in equity; and the parties hereto further agree to waive any requirement
for the securing or posting of any bond in connection with the obtaining of any such injunctive or
other equitable relief.

          (b) Each party agrees that there shall be no special, exemplary, punitive or multiple damages
connected with or resulting from any breach of this Agreement, or actions undertaken in connection
with or related hereto, including any such damages which are based upon breach of contract, tort,
breach of warranty, strict liability, statute, operation of law or any other theory of recovery,
except to the extent such damages are actually incurred by a party hereunder to a third party, and
hereby waives any rights to claim such damages. For purposes of clarity, the foregoing does not
exclude consequential, indirect or incidental damages. Notwithstanding anything to the contrary in
the foregoing, no damages (including lost profits) based on potential appreciation of the value of
the Common Stock or of hypothetical investment returns or of potential alternative investments
shall be taken into account in determining the amount of damages.

     Section 5.12 Counterparts. This Agreement may be executed in any number of counterparts, each
of which shall be an original, but all of which together shall constitute one instrument.

[Remainder of Page Intentionally Left Blank.]

32

 

     IN WITNESS WHEREOF, the parties hereto have executed this Amended and Restated Stockholder
Agreement as of the date first set forth above.

	 	 	 	 	 
	 	TRIDENT MICROSYSTEMS, INC.

 	 
	 	By:  	/s/
David L. Teichmann	 
	 	 	Name:  	David L. Teichmann	 
	 	 	Title:  	Executive Vice President, General Counsel & Corporate Secretary

Trident Microsystems, Inc.	 
	 
	 	NXP B.V.

 	 
	 	By:  	/s/
James N. Casey	 
	 	 	Name:  	James N. Casey	 
	 	 	Title:  	V.P. (authorized signatory)	 
	 

 

EXHIBIT A

Defined Terms

     “ADTV” means, as of any trading day, the average daily reported trading volume for the Common
Stock on all national securities exchanges for the twelve full calendar weeks immediately preceding
such trading day.

     “Activist Investor” means, as of any date of determination, a Person that has, within the five
year period immediately preceding such date of determination, (i) made or been a “participant” in
any “solicitation” of “proxies” (as such terms are used in Regulations 14A or 14C under the
Exchange Act) for an issuer’s equity securities in connection with a proposed Change of Control or
a proposal for the election or replacement of directors not approved (at the time of the first such
proposal) by the board of directors of such issuer, or (ii) commenced a “tender offer” (as such
term is used in Regulation 14D under the Exchange Act) to acquire the equity securities of an
issuer that was not approved (at the time of commencement) by the board of directors of such issuer
in a Schedule 14D-9 filed under such Regulation 14D, or (iii) publicly indicated an intention or
expectation to do any of the foregoing.

     “Affiliate” means, with respect to any Person, means any other Person that directly, or
indirectly through one (1) or more intermediaries, controls, or is controlled by or under common
control with such Person. For purposes of this definition, “control” (including the terms
“controlling,” “controlled” and “under common control with”) means the possession, direct or
indirect, of the power to direct or cause the direction of the management and policies of a Person,
whether through the ownership of voting securities, by contract or otherwise; provided, that
possession of ten percent (10%) of the voting securities of any Person shall be deemed to
constitute “control” for purposes of this Agreement.

     “Amended and Restated Certificate of Designation” means the Amended and Restated Certificate
of Designation in the form attached hereto as Exhibit D

     “Beneficially Own” and “Beneficial Ownership” and similar terms have the meaning set forth in
Rule 13d-3 under the Securities and Exchange Act of 1934, as amended.

     “Board” means the Board of Directors of the Company.

     “Business Day” means any day that is not a Saturday, a Sunday or other day on which banks are
required or authorized by law to be closed in New York, New York.

     “Bylaws” means the Bylaws of the Company, as in effect on the Agreement Date and as the same
may be amended, supplemented or otherwise modified from time to time in accordance with the terms
thereof and the terms of the Certificate of Incorporation.

     “Capital Stock” means any and all shares of capital stock of the Company, including without
limitation, any and all shares of Common Stock and Preferred Stock.

     “Certificate of Designation” means the Certificate of Designation with respect to the
Company’s Series B Preferred Stock, par value $0.001 per share, as the same may be amended,

A-1

 

supplemented or otherwise modified from time to time in accordance with the terms thereof and
hereof, including the Amended and Restated Certificate of Designation.

     “Certificate of Incorporation” means the Second Amended and Restated Certificate of
Incorporation (including the Certificate of Designation) of the Company, as in effect on the
Agreement Date and as the same may be amended, supplemented or otherwise modified from time to time
in accordance with the terms thereof and the terms of this Agreement.

     “Change of Control” means any of: (a) the purchase or other acquisition by any Person or group
of Persons, directly or indirectly, in one transaction or a series of related transactions, of
Common Stock that, immediately following consummation of the transaction(s), when combined with any
other Common Stock Beneficially Owned by such Person or group, represent more than fifty percent
(50%) of the Diluted Common Shares Outstanding; (b) the consummation of any tender offer or
exchange offer by any Person or group that results in such Person or group Beneficially Owning,
when combined with any other Common Stock Beneficially Owned by such Person or group, more than
fifty percent (50%) of the Diluted Common Shares Outstanding immediately following the consummation
of such tender or exchange offer; (c) the consummation of a merger, consolidation, amalgamation,
joint venture, business combination or other similar transaction involving the Company pursuant to
which the stockholders of the Company immediately preceding such transaction hold less than fifty
percent (50%) of the voting equity interests in the surviving or resulting entity of such
transaction; or (d) the purchase or other acquisition of a substantial portion of the assets of the
Company by any Person or group of Persons.

     “Committee Qualification Requirements” shall mean that the Series B Director shall, in the
good faith judgment of the Board, meet at all times during the Series B Director’s service on a
particular committee: (i) all independence requirements applicable to companies listed for
quotation on any Exchange on which the Common Stock is listed for members of the particular
committee pursuant to Exchange listing requirements and applicable law, (ii) in the case of the
Compensation Committee, be a “non-employee director” (within the meaning of Rule 16b-3) and an
“outside director” (within the meaning of Section 162(m) of the Internal Revenue Code of 1986, as
amended, and the regulations thereunder), and (iii) in the case of the Audit Committee, satisfy the
requirements of NASDAQ Marketplace Rule 5605(c) and any other requirements of any Exchange on which
the Common Stock is listed for serving on the Audit Committee.

     “Company Competitor” means any Person listed on Exhibit B hereto, together with any
Subsidiaries or controlled Affiliates of such Person. The Company shall be entitled to amend
Exhibit B annually by adding or substituting Persons reasonably believed by the Company to
be significant competitors of the Company and deleting Persons no longer reasonably believed to be
significant competitors of the Company. The Company will consult in good faith with Investor
regarding any proposed amendment of Exhibit B, but any such amendment shall be in the
Company’s sole discretion and Investor shall have no right to approve or object to any such
amendment.

     “Common Stock” means the Common Stock, par value $0.001 per share, of the Company and any
securities issued in respect thereof, or in substitution therefor, in connection

A-2

 

with any stock split, dividend or combination, or any reclassification, recapitalization,
merger, consolidation, exchange or other similar reorganization.

     “Confidentiality Agreement” means the confidentiality agreement, dated as of January 14, 2009
between the Company and the Investor.

     “Convertible Securities” means any outstanding securities which are convertible into,
exchangeable for or otherwise exercisable to acquire Voting Stock of the Company, including
convertible securities, warrants, rights or options to purchase Voting Stock.

     “Diluted Common Shares Outstanding” means the sum of (i) the number of outstanding shares of
Common Stock plus (ii) the number of shares of Common Stock issuable upon the conversion, exercise,
exchange or issuance of any other Equity Securities of the Company.

     “Director” means any member of the Board.

     “Economic Rights” means, with respect to a security, (i) the right to any pecuniary interest
in the security, including, without limitation, the right to receive dividends and distributions,
proceeds upon liquidation and receive the proceeds of disposition or conversion (if applicable) of
the security, (ii) or the right or ability to realize any profit or loss based on changes in the
trading price of the security, whether by means of any hedging, swap, option, short sale,
borrowing, lending, put, call or other derivative transaction or agreement.

     “Eligible Transferee” means any Person other than an Ineligible Transferee.

     “Equity Securities” means (a) any Capital Stock of the Company (including, without limitation,
Common Stock), (b) any warrants, options, or other rights to subscribe for or to acquire, directly
or indirectly, Capital Stock of the Company, whether or not then exercisable or convertible, (c)
any stock, notes, or other securities which are convertible into or exchangeable for, directly or
indirectly, Capital Stock of the Company, whether or not then convertible or exchangeable, (d) any
Capital Stock of the Company issued or issuable upon the exercise, conversion, or exchange of any
of the securities referred to in clauses (a) through (c) above, and (e) any securities issued or
issuable directly or indirectly with respect to the securities referred to in clauses (a) through
(d) above by way of stock dividend or stock split or in connection with a combination of shares,
recapitalization, reclassification, merger, consolidation, or other reorganization.

     “Exchange” means the stock exchange on which the Company’s securities are then traded, as the
case may be. For the avoidance of doubt, The NASDAQ Stock Market, or any successor thereto, shall
constitute an Exchange for purposes of this Agreement.

     “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder.

     “First Tier Affiliate” means any of (i) any Subsidiary of the Investor and (ii) the Persons
listed in Exhibit C hereto.

A-3

 

     “Governmental Authority” means any: (A) nation, state, commonwealth, province, territory,
county, municipality, district or other jurisdiction of any nature; (B) national, federal, state,
local, municipal, foreign or other government; (C) governmental authority of any nature (including
any governmental division, department, agency, commission, instrumentality, official, ministry,
fund, foundation, center, organization, unit, body or Entity and any court or other tribunal); or
(D) entity to whom a Governmental Authority has assigned or delegated any authority or oversight
responsibilities.

     “Independent Director” means a Director who is independent of the Company under applicable law
and the rules of the Exchange.

     “Ineligible Transferee” means a Strategic Investor or an Activist Investor.

     “Investor Maximum Ownership Percentage” shall initially mean sixty percent (60%). Thereafter,
upon the disposition by the Investor or its Affiliates of any Common Stock or other Equity
Securities to any Person other than a Permitted Transferee, the Investor Maximum Ownership
Percentage shall be reduced to an amount (expressed as a percentage) equal to the lesser of (a) the
Investor Maximum Ownership Percentage immediately prior to such disposition, and (b) a fraction, of
which the numerator is the number of shares of Voting Stock Beneficially Owned by the Investor and
its Affiliates immediately following such disposition and the denominator of which is the total
number of shares of Voting Stock outstanding immediately following such disposition. The Investor
Maximum Ownership Percentage shall not be adjusted other than following dispositions of Equity
Securities by the Investor or its Affiliates to Persons other than the Investor and its Permitted
Transferees; provided, that if (i) pursuant to Section 3.1 Investor is offered the opportunity to
purchase Equity Securities in any Offering and does not elect to purchase its full Pro Rata Share
in such Offering, and (ii) within one year after the closing of such Offering Investor has not
purchased (in the manner provided in Section 3.2(b)) additional shares of Common Stock equal to the
difference between Investor’s Pro Rata Share of such Offering and the number of shares of Common
Stock actually purchased by Investor under Section 3.1 in connection with such Offering, then the
Investor Maximum Ownership Percentage shall be reduced as if (x) Investor had purchased its full
Pro Rata Share in such Offering and (y) Investor had thereafter sold a number of shares of Common
Stock equal to the amount (if any) by which such Pro Rata Share exceeds the sum of (A) the number
of share of Common Stock actually purchased by Investor under Section 3.1 in connection with such
Offering and (B) the number of shares of Common Stock actually purchased by Investor in the manner
provided in Section 3.2(b) during the one-year period immediately following the closing of such
Offering. Once reduced, the Investor Maximum Ownership Percentage shall never be increased
following any subsequent disposition or acquisition of Common Stock or other event or transaction.
The Investor Maximum Ownership Percentage shall never exceed sixty percent (60%).

     “Investor Registrable Securities” means (i) the Common Shares and any Common Stock acquired
pursuant to Section 3.1 hereof, (ii) all shares of Common Stock transferred to any Person in
accordance with clause (3) of Section 2.1(b)(i), or (iii) any shares of Common Stock issued or
issuable with respect to any other Equity Securities acquired pursuant to Section 3.1 upon
conversion or exercise of any security directly or indirectly convertible into or exchangeable or
exercisable for shares of Common Stock or (iv) any Common Stock issued with respect to any of the
foregoing by way of a stock dividend or stock split or in connection with a

A-4

 

combination of shares, recapitalization, merger, consolidation or other reorganization. As to
any particular Investor Registrable Securities, such securities shall cease to be Investor
Registrable Securities when (a) a Registration Statement with respect to the sale of such
securities has become effective under the Securities Act and such securities have been disposed of
in accordance with the plan of distribution set forth in such Registration Statement, (b) they have
been sold to the public through a broker, dealer, or market maker in compliance with Rule 144 under
the Securities Act, (c) they have been repurchased by the Company or any Subsidiary thereof, (d)
they have been transferred as provided in Section 2.1(b)(ii) hereof (provided, that shares so
transferred shall nonetheless be entitled to piggyback registration rights as provided in Section
4.2 and shall be considered Investor Registrable Securities solely for purposes of participation in
such a Piggyback Registration), (e) they have been transferred as contemplated by clause (1) of
Section 2.1(b) hereof or by Section 2.1(c)(v) hereof, (f) in the case of a holder which is a
limited partnership or limited liability company, unless such holder otherwise elects, when they
have been distributed to the partners or members of such holder, (g) they have been otherwise
transferred, new certificates for them not bearing a legend restricting further transfer shall have
been delivered by the Company and subsequent public distribution of them shall not require
registration under the Securities Act, or (h) all of such securities held by an Investor may be
sold without volume or manner of sale restrictions pursuant to Rule 144 under the Securities Act;
provided, that nothing in this sentence shall be deemed to permit any Transfer of any Common Stock
or other Equity Security other than in full compliance with Section 2.1 hereof. For purposes of
this Agreement, a Person shall be deemed to be a holder of Investor Registrable Securities, and the
Investor Registrable Securities shall be deemed to be in existence, whenever such Person has the
right to acquire directly or indirectly such Investor Registrable Securities (upon conversion or
exercise in connection with a transfer of securities or otherwise, but disregarding any
restrictions or limitations upon the exercise of such right), whether or not such acquisition has
actually been effected, and such Person shall be entitled to exercise the rights of a holder of
Investor Registrable Securities hereunder.

     “Liquidation Proceeding” means any liquidation, dissolution or winding up of the Company or
any of its Subsidiaries or the commencement of proceedings to adjudicate the Company or any of its
Subsidiaries as bankrupt, or consenting to the filing of a bankruptcy proceeding against any of
them, or filing a petition or answer or consent seeking reorganization of any of them under any
bankruptcy or insolvency law, or consenting to the filing of any such petition, or consenting to
the appointment of a receiver or liquidator or trustee or assignee in bankruptcy or insolvency, or
making an assignment for the benefit of creditors, or admitting inability to pay debts generally as
they become due.

     “Material Adverse Change” means (i) any general suspension of trading in, or limitation on
prices for, securities on any national securities exchange or in the over-the-counter market in the
United States; (ii) the declaration of a banking moratorium or any suspension of payments in
respect of banks in the United States; (iii) a material outbreak or escalation of armed hostilities
or other international or national calamity involving the United States or the declaration by the
United States of a national emergency or war; and (iv) any event, change, circumstance or effect
that is or is reasonably likely to be materially adverse to the business, properties, assets,
liabilities, financial condition, operations or results of operations of the Company and its
subsidiaries taken as a whole.

A-5

 

     “Offering” means (i) a firm commitment underwritten public offering of shares of Common Stock
by the Company, or (ii) any offering or sale of Common Stock or of Equity Securities convertible
into, or exchangeable or exercisable for, Common Stock by the Company conducted primarily for
financing purposes (and expressly excluding offers or sales of Common Stock or other Equity
Securities offered or issued (A) to directors, officers or employees of the Company or its
Subsidiaries (excluding the Investor or any of its Affiliates) pursuant to incentive compensation
plans or similar arrangements approved by the Board, or (B) in connection with any stock split,
stock consolidation or stock dividend or any recapitalization in which all of the Company’s
stockholders are treated in the same manner and which does not affect the percentage of the
outstanding shares owned by the Investor, or (C) in any merger, consolidation or business
combination approved by the Board, or (D) as consideration for the purchase of any assets or
securities of any other Person, in a transaction approved by the Board).

     “Other Registrable Securities” means the Common Stock issued or issuable upon the exercise,
conversion or exchange of all Equity Securities subject to any contractual or other right of
registration with the Company, excepting such Equity Securities as are unvested, subject to
repurchase by the Company or otherwise not then exercisable, convertible or exchangeable into
Common Stock.

     “Own” and “Ownership” shall mean, with respect to any Person and any Series B Shares, that
such Person is the record owner of such Series B Shares.

     “PE Investor” shall mean any entity that is commonly referred to as a “private equity fund” or
a “venture capital firm”. This definition is intended to apply to any entity that (i) qualifies
under an exclusion from the definition of “investment company” under Section 3(c)(1) or 3(c)(7) of
the Investment Company Act of 1940, (ii) is intended to be of limited duration and (iii) is
primarily in the business of using capital to purchase assets, businesses or securities with the
intention of profiting (or enabling its general or limited partners, members or shareholders to
profit) from the resale of such assets, businesses or securities or, in the case of non-controlling
investments, from distributions from entities in which such non-controlling investments are made).

     “Permitted Transferee” means the Company or any of its Subsidiaries or any First Tier
Affiliate of the Investor that is not a Company Competitor. In the event that any First Tier
Affiliate of the Investor, subsequent to a Transfer hereunder, ceases to be a Permitted Transferee
(any such cessation, a “Disqualifying Event”), such Disqualifying Event shall be considered a
Transfer and shall be subject to the terms hereof with respect thereto, including Section 2.1. If
such Transfer fails to comply with the provisions of Section 2.1, such Person that shall have
ceased to be a First Tier Affiliate as a result of such Disqualifying Event shall cease to be
considered an Investor or Permitted Transferee for any purpose hereunder, but for all purposes of
Sections 1.3, 1.5, 2.1 and 3.2, such Person shall continue to be bound by the provisions of this
Agreement as an Investor.

     “Person” means any natural person, corporation, limited liability company, trust, joint
venture, association, company, partnership, governmental authority or other entity.

A-6

 

     “Preferred Stock” means the shares of preferred stock, par value $0.001 per share, of the
Company and any securities issued in respect thereof, or in substitution therefor, in connection
with any stock split, dividend or combination, or any reclassification, recapitalization, merger,
consolidation, exchange or other similar reorganization.

     “Pro Rata Share” means, for any Investor, such number of Equity Securities (of the same type
as the Equity Securities being sold in the Offering) as shall equal the product obtained by
multiplying (i) the quotient obtained by dividing (A) the number of shares of Common Stock (on an
as converted basis) Beneficially Owned by such Investor, by (B) the number of Diluted Common Shares
Outstanding as of the most recent practicable date prior to the Offering, by (ii) the aggregate
number of such Equity Securities being sold in the Offering.

     “Public Offering” means a public offering of shares of Common Stock pursuant to an effective
registration statement (other than a registration statement on Form S-8 or Form S-4, or their
successors, or any other form for a similar limited purpose) under the Securities Act that meets
the requirements of Section 2.1(c)(iii).

     “Registrable Securities” means the Investor Registrable Securities and Other Registrable
Securities.

     “Registration Statement” shall mean any registration statement filed by the Company with the
SEC for a Public Offering under the Securities Act (other than a registration statement on Form S-8
or Form S-4, or their successors, or any other form for a similar limited purpose) and all
amendments and supplements to any such Registration Statement, including pre- and post-effective
amendments, in each case including the prospectus contained therein, all exhibits thereto and all
material incorporated by reference (or deemed to be incorporated by reference) therein.

     “Right to Maintain Period” means the period beginning on the Agreement Date and ending upon
the earliest to occur of (i) the first date on which the Investor (or one of its Affiliates) ceases
to own at least one Series B Share, (ii) the first date on which the Investor and its Affiliates
collectively own less than eleven percent (11%) of the outstanding Voting Stock, and (iii) a Change
of Control.

     “Rights Agreement” means the Amended and Restated Rights Agreement between the Company and
Mellon Investor Services, LLC, as Rights Agent dated as of July 23, 2008, as amended from time to
time.

     “SEC” means the U.S. Securities and Exchange Commission or any other federal agency then
administering the Securities Act or the Exchange Act and other federal securities laws.

     “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder.

     “Standstill Limit” shall mean, at any time and with respect to any contemplated acquisition of
Equity Securities by the Investor or any of its Affiliates, a number of shares of Common Stock
equal to the product of (x) the Investor Maximum Ownership Percentage at such time and (y) the
number of outstanding shares of Common Stock.

A-7

 

     “Strategic Investor” means, with respect to the Company, a Person that (whether directly or
through one or more Subsidiaries) (a) conducts business in the same industry as that in which the
Company conducts business (or in an industry functionally related to the industry in which the
Company conducts business), or (b) develops, manufactures, licenses or sells products, services or
technology that are of relevance to, or are reasonably likely in the future to be of relevance with
respect to, a strategic transaction involving the purchase of equity securities of the Company, in
each case whether or not such purchases or equity securities are registered under the Securities
Act; provided that the term “Strategic Investor” shall not include any PE Investor.

     “Subsidiary” means, with respect to any Person, each and all corporations, partnerships,
limited liability companies, limited liability partnerships, joint ventures or other entities (A)
of which such Person owns (directly or indirectly, beneficially or of record) at least a fifty
percent (50%) equity, beneficial or financial interest; (B) of which such Person owns (directly or
indirectly, beneficially or of record) an amount of voting securities of other interests sufficient
to enable such Person to elect at least a majority of the members of such entity’s board of
directors or other governing body; or (C) that is otherwise, directly or indirectly, controlled by
such Person.

     “Superior Proposal” means a bona fide written proposal with respect to a Change of Control
transaction by a third party that is determined by Board, in its good faith judgment, after
consultation with a financial advisor of nationally recognized reputation, and after taking into
account the likelihood and anticipated timing of consummation and all legal, financial and
regulatory aspects of the offer and the Person making the offer, to be more favorable from a
financial point of view to the Company’s stockholders than a transaction proposed by the Investor
under Section 3.2(d).

     “13D Group” means any group of Persons formed for the purpose of acquiring, holding, voting or
disposing of Equity Securities which would be required under Section 13(d) of the Exchange Act, and
the rules and regulations promulgated thereunder, to file a statement on Schedule 13D (a “Schedule
13D”) pursuant to Rule 13d-1(a) of the rules and regulations promulgated under the Exchange Act or
a Schedule 13G of the rules and regulations promulgated under the Exchange Act pursuant to Rule
13d-1(c) of the rules and regulations promulgated under the Exchange Act with the SEC as a “person”
within the meaning of Section 13(d)(3) of the Exchange Act if such group Beneficially Owns Equity
Securities representing more than five percent (5%) of any class of Equity Securities then
outstanding.

     “Transfer” means, directly or indirectly, to sell, transfer, assign, pledge, encumber,
hypothecate or similarly dispose of, either voluntarily or involuntarily, or to enter into any
contract, option or other arrangement or understanding with respect to the sale, transfer,
assignment, pledge, encumbrance, hypothecation or similar disposition of, any Common Stock or
Series B Shares Beneficially Owned by a Person or any interest (including any Economic Rights or
Voting Rights) in any Common Stock or Series B Shares Beneficially Owned by a Person, and any
transaction which would have the same effect, or any swap, hedge or other arrangement that
transfers, in whole or in part, any economic consequences of ownership of any Common Stock, whether
any such aforementioned transaction is to be settled by delivery of Common Stock or other
securities, in cash or otherwise,. “Transferred” shall have the correlative meaning.

A-8

 

     “Transferee” means any Person to whom any Investor or any Permitted Transferee or any
Transferee thereof Transfers Equity Securities of the Company in accordance with the terms hereof.

     “Underwritten Registration” or “Underwritten Offering” shall mean a sale of securities of the
Company to an underwriter for reoffering to the public pursuant to an effective Registration
Statement.

     “U.S. GAAP” means United States generally accepted accounting principles.

     “U.S. GAAS” means United States generally accepted auditing standards.

     “Voting Rights” means any rights to vote, or cause or direct any other Person to vote, any
shares of Common Stock, whether conditional or unconditional, and whether limited to specified
matters or generally.

     “Voting Stock” means any Equity Securities of the Company or its successor having the power to
vote in the election of Company Nominated Directors or members of the board of directors of the
Company’s successor (including voting in accordance with Section 1.3 hereof), including, without
limitation, all shares of Common Stock.

A-9

 

EXHIBIT B

Company Competitors

Broadcom Corp.

Conexant Systems, Inc.

Intel Corp.

LG Corp.

Marvell Technology Group Ltd.

MediaTek Inc.

MStar Semiconductor Inc.

NEC Corp.

Novatek Microelectronics Corp.

Panasonic Corp.

Koninklijke Philips Electronics NV

Pixelworks, Inc.

Renesas Technology Corp.

Samsung Electronics Co., Ltd.

Sigma Designs, Inc.

Sunplus Technology Co., Ltd.

Sony Corp.

STMicroelectronics N.V.

Toshiba Corp.

Zoran Corp.

B-1

 

EXHIBIT C

First Tier Affiliates

1. Koninklijke Philips Electronics N.V. and any of its Subsidiaries

2. KASLION Acquisition B.V.

3. Stichting Management Co-Investment NXP

4. KASLION Holding B.V.

5. KASLION S.a.r.l.

6. Investment funds affiliated with or managed or advised by Kohlberg Kravis Roberts &
Co. (KKR), including KKR European Fund II, Limited Partnership

7. Investment funds affiliated with or managed or advised by Bain Capital, including Bain
Capital Fund IX, L.P. and Bain Capital Fund VIII-E, L.P.

8. Investment funds affiliated with or managed or advised by Silver Lake Partners, including
Silver Lake Partners II Cayman, L.P.

9. Investment funds affiliated with or managed or advised by Apax, including Apax Europe
V-A, L.P. and Apax Europe VI-A, L.P.

10. Investment funds affiliated or managed or advised by with Alplnvest Partners CS
Investments 2006 C.V.

As well as any Subsidiary of any entity listed in items 2-5 of this Exhibit C that at the
relevant time of determination beneficially owns shares of NXP B.V. (provided that (a) such
Subsidiary shall be a Permitted Transferee only for so long as it remains a Subsidiary of such
entity and (b) in the event that such Subsidiary ceases to be a Subsidiary of such entity, that
event shall be considered a Transfer and shall be subject to the terms of the Agreement with
respect to Transfers, including Section 2.1).

C-1

 

EXHIBIT D

Amended and Restated Certificate of Designation

C-2

 

AMENDED AND RESTATED

CERTIFICATE OF DESIGNATION OF

SERIES B PREFERRED STOCK

(Par Value $0.001)

OF

TRIDENT MICROSYSTEMS, INC.

Pursuant to Section 151 and Section 242 of the

General Corporation Law of the State of Delaware

     Trident Microsystems, Inc., a corporation organized and existing under the General Corporation
Law of the State of Delaware (the “Company”), in accordance with the provisions of Section
151 thereof, DOES HEREBY CERTIFY:

     That pursuant to the authority conferred upon the Board of Directors of the Company (the
“Board”) in accordance with the Restated Certificate of Incorporation of the Company, as
amended to date (the “Certificate of Incorporation”), and the Amended and Restated Bylaws
of the Company, as amended to date (the “Bylaws”), the Board on [April 28, 2011] adopted
the following resolution amending and restating the rights of the Series B Preferred Stock:

     WHEREAS, the holders of the Series B Preferred Stock have approved the form of this Amended
and Restated Certificate of Designation of the Series B Preferred Stock; and

     WHEREAS, the outstanding shares of common stock of the Company have approved the amendment of
the Certificate of Incorporation pursuant to Section 242 of the

     General Corporation Law of the State of Delaware to amend and restate the rights of the Series
B Preferred Stock as set forth in this Amended and Restated Certificate of Designation of Series B
Preferred Stock.

     RESOLVED, that the rights set forth in the Certificate of Designation of Series B Preferred
Stock, are hereby amended and restated as follows:

Section 1. Number of Shares and Designation.

     The designation of the series of Preferred Stock created by this resolution shall be “Series B
Preferred Stock” (the “Series”), and the number of shares constituting this Series shall be
four (4) (the “Series B Shares”). Each Series B Share shall have a liquidation preference
of $1.00 (the “Liquidation Preference”), as described herein. The number of authorized
shares of this Series shall not be increased or reduced without (in addition to any other vote
required by law) (1) the approval of both a majority of the Series B Directors and a majority of
the Company Nominated Directors (as defined in Section 4) and (2) the approval of the
Persons who Own the Series B Shares (the “Series B Holders”), voting as a separate class to
the exclusion of all other series or classes of the Equity Securities.

C-3

 

Section 2. Dividends.

     No dividends (whether payable in cash, in property or in Equity Securities) shall be payable
in respect of the Series B Shares.

Section 3. Redemption.

     (a) The Series B Shares shall not be redeemable by the Company except that all of the Series B
Shares may be redeemed, at the option of the Company at a redemption price of $1.00 per share, if
at any time following the filing of this Certificate of Designation with the Secretary of State of
the State of Delaware the Series B Holders no longer Beneficially Own, in the aggregate, eleven
percent (11%) or more of the outstanding shares of Common Stock.

     (b) Notice of redemption of the Series B Shares shall be sent by or on behalf of the Company,
by first class mail, postage prepaid, to each Series B Holder who Owns Series B Shares to be
redeemed) at its address as it shall appear on the records of the Company, (i) notifying each
Series B Holder of the redemption of the Series B Shares (or, in the case of a redemption of less
than all of the Series B Shares, notifying the Series B Holder who Owns the Series B Shares to be
redeemed) and (ii) stating the place at which the certificates evidencing the Series B Shares shall
be surrendered. The Company shall act as the transfer agent for the Series.

     (c) From and after the notice of redemption having been duly given, and the redemption price
having been paid or irrevocably set aside for payment, the Series B Shares with respect to which
such notice has been given and such redemption price paid or set aside shall no longer be, or be
deemed to be, outstanding for any purpose, and all rights preferences and powers (including voting
rights and powers) of such Series B Shares shall automatically cease and terminate, except the
right of the Persons who Own such Series B Shares, upon surrender of the certificate representing
such Series B Shares, to receive the redemption price without interest.

Section 4. Voting Rights of the Series B Shares.

     (a) Board Representation.

     (i) For so long as the Series B Holders shall be entitled to nominate and elect at least one
(1) Director pursuant to this Section 4(a), the Board shall consist of a number of
Directors of seven (7) to nine (9) with the specific number of Directors at any time to be fixed by
the Board by the adoption of a resolution by a majority of the number of Directors then in office
(whether or not there exist any vacancies in the previously authorized number of directorships at
the time such resolution is presented). The Board shall at all times consist of at least a
majority of Directors who are Independent Directors.

     (ii) Subject to Section 4(a)(iv), so long as the Series B Holders Beneficially Own, in
the aggregate, less than thirty percent (30%) but at least twenty percent (20%) of the outstanding
Common Stock, the Series B Holders (by majority vote of the Series B Shares) shall have the right
to nominate and elect a total of two (2) Series B Directors.

     (iii) Subject to Section 4(a)(iv), so long as the Series B Holders Beneficially Own,
in the aggregate, less than twenty percent (20%) but at least eleven percent (11%) of the

C-4

 

outstanding Common Stock, the Series B Holders (by majority vote of the Series B Shares) shall
have the right to nominate and elect one (1) Series B Director.

     (iv) The number of Series B Directors which the Series B Holders shall be entitled to nominate
and elect shall not be reduced unless and until the number of Series B Shares Beneficially Owned by
the Series B Holders shall be less than the applicable threshold set forth in Section 4(a)(ii)
and (iii)above for a period of thirty (30) consecutive days. After any such reduction, the
number of Series B Directors which the Series B Holders shall be entitled to nominate and elect
shall not be increased regardless of any subsequent increase in the percentage of outstanding
Common Stock Beneficially Owned by the Series B Holders.

     (v) No person other than the Series B Holders shall be entitled to nominate a Series B
Director.

     (vi) The Board and its Nominating and Corporate Governance Committee shall be entitled to
nominate the individuals for election to the remaining seats on the Board other than the seats held
by the Series B Directors (the “Company Nominated Directors.”)

     (vii) The Company shall notify the Series B Holders promptly, and in any event within five (5)
Business Days, of any issuance of Common Stock representing, individually or together with all
issuances of Common Stock since the date of the filing of this Certificate of Designation with the
Secretary of State of the State of Delaware or the date of any previous such notice, as applicable,
one percent (1%) or more of the outstanding Common Stock as of the date of such filing or such
previous notice together with the aggregate number of shares of Common Stock outstanding following
such issuance.

     (viii) The Series B Holders will notify the Company promptly, and in any event within five (5)
Business Days, of any action by the Series B Holders or any of their Affiliates (other than the
Company) that results in a reduction in the number of shares of Common Stock that are Beneficially
Owned by the Series B Holders representing, individually or together with all such reductions since
the date of the filing of this Certificate of Designation with the Secretary of State of the State
of Delaware or the date of any previous such notice, as applicable, one percent (1%) or more of the
outstanding Common Stock as of the date of such filing or such previous notice, which notice will
set forth the number of shares of Common Stock Beneficially Owned by the Series B Holders
immediately following the occurrence of such reduction; provided, that for purposes of this
provision, in determining the shares of Common Stock outstanding the Series B Holders may rely upon
the Company’s most recent periodic report filed with the SEC, or any update thereof, or any notice
provided by the Company pursuant to Section 4(a)(ix). In the event that the number of directors
that the Series B Holders are entitled to nominate and elect to the Board is reduced pursuant to
this Section 4(a), the Series B Holders shall promptly cause one (1) or more of the Series
B Directors to immediately resign, such that the number of remaining Series B Directors serving on
the Board shall equal the number of directors the Series B Holders are then entitled to elect to
the Board pursuant to this Section 4(a). In the event that the number of Series B
Directors required to resign are unwilling to resign, the Series B Holders will take all such
actions as are necessary to cause the removal of such number of Series B Directors. If such number
of Series B Directors shall not have resigned or been removed within thirty (30) days after the
date on which such resignation was required, the

C-5

 

Company Nominated Directors, by majority vote, may remove the Series B Director(s) selected by
the Series B Holders for removal, or if no such Series B Directors have been so selected by the
Series B Holders within ten (10) Business Days of a request from the Company, the Company Nominated
Directors, by majority vote, may remove one or more Series B Directors selected by them, such that,
in the aggregate, the number of Series B Directors required to be removed under this Section
4(a)(xi) have been removed.

     (b) Term; Replacement of Directors.

          (i) As of the date of this Amended and Restated Certificate of Designation (the “Amendment
Date”), one Series B Director shall be a member of the class of Directors whose term expires at
the first annual meeting of the Company’s stockholders following the Amendment Date, and one Series
B Director shall be a member of the class of Directors whose term expires at the second annual
meeting of the Company’s stockholders following the Amendment Date. Any Series B Director may, at
any time, be removed with or without cause by the Series B Holders by majority vote of the Series B
Shares.

          (ii) In the event of any vacancies on the Board resulting from the death, resignation,
retirement, disqualification, removal or other cause of any of the Series B Directors, other than
any vacancies created as a result of a reduction in the number of Series B Directors that the
Series B Holders are entitled to elect pursuant to Section 4(a), then the Series B Holders
shall have the sole right (by majority vote of the Series B Shares) to nominate and elect directors
to fill such vacancies so long as such Series B Shares remain outstanding. Any director elected
pursuant to this Section 4(b)(ii) to succeed a Series B Director shall be considered a
Series B Director.

          (iii) Any vacancies created as a result of a reduction in the number of Series B Directors
that the Series B Holders are entitled to elect pursuant to Section 4(a) shall be filled by
nominees (A) who satisfy the requirements of Section 4(c) below, and (B) are recommended by
the Nominating and Corporate Governance Committee and approved by the Board. The Director(s)
appointed to fill such vacancy shall stand for re-election at the next annual meeting of the
Company’s stockholders following such appointment and shall, if elected, serve for the remaining
term of the Series B Director(s) that such Director(s) replaced (or, if such term expired at such
annual meeting, for the full term otherwise applicable to Directors of the class elected at such
meeting).

          (iv) The nomination, election, replacement, removal and term of the Company Nominated
Directors and the filling of any vacancies on the Board resulting from the death, resignation,
retirement, disqualification, removal or other cause of any of the Company Nominated Directors
shall be governed by the Certificate of Incorporation and Bylaws of the Company, applicable law and
the Stockholder Agreement. Any director elected to succeed a Company Nominated Director shall be
considered a Company Nominated Director for all purposes.

     (c) Limitations on Directors. Each Director shall, at all times during which such
Person serves as a Director, not have been during the last five (5) years convicted in a criminal
proceeding (excluding traffic violations or other misdemeanors not involving moral turpitude or

C-6

 

deliberate dishonesty) or a party to a civil proceeding brought by a governmental authority in
which such Director has been finally determined to have committed a violation of federal, state or
foreign law (excluding traffic violations or similar misdemeanors not involving moral turpitude or
deliberate dishonesty). The Series B Holders shall not nominate or elect any such Series B
Director who does not meet the requirements set forth in this Section 4(c) and shall cause
any such Series B Director who fails to meet the requirements set forth above to resign promptly.
If any such Series B Director is unwilling to resign, the Series B Holders will take such actions
as are necessary to cause the removal of the Series B Director as promptly as reasonably
practicable. If any such Series B Director shall not have resigned or been removed within thirty
(30) days after the date such resignation was required, the Company Nominated Directors, by
majority vote, may remove such Series B Director.

     (d) Limitations on Series B Directors. Each of the Series B Directors shall have
substantial operating or industry experience and shall be a Person who is an Independent Director.
The Series B Holders shall consult with the Nominating and Corporate Governance Committee (which
may delegate such consultation to the Committee Chairperson and/or the Chief Executive Officer of
the Company) regarding the names, backgrounds and qualifications of the persons to be nominated as
Series B Directors after considering the Company’s Corporate Governance Guidelines (as made
publicly available from time to time). However, the Nominating and Corporate Governance Committee
shall not have any right nor shall it have any duty to approve or disapprove any person meeting the
requirements of Section 4(c) selected as a Series B Director by the Series B Holders.

     (e) Approval Rights. In addition to any other vote required by law, the affirmative
vote of the Series B Holders, voting separately as a class, given in person or by proxy, shall be
necessary for authorizing, approving or effecting the amendment, alteration or repeal of any of the
provisions of the Certificate of Incorporation or this Certificate of Designation, whether by
merger, consolidation, amendment or otherwise, that would adversely affect the powers,
designations, preferences and other special rights of the Series B Shares, other than a merger,
consolidation or other business combination with a Person that is not an Affiliate of the Company
or the Series B Holders that results in a Change of Control.

     (f) No Additional Voting Rights. Other than as specifically set forth in this
Section 4 and unless otherwise required by applicable law, the Series B Shares shall not be
entitled to a separate vote on any matter.

Section 5. Liquidation Rights.

     (a) Upon the dissolution, liquidation or winding up of the Company, each Series B Share shall
be entitled to receive and to be paid out of the assets of the Company available for distribution
to its stockholders, before any payment or distribution shall be made on the Common Stock or on any
other class of stock ranking junior to the Preferred Stock upon liquidation, the amount of $1.00,
and no more.

     (b) Neither the sale of all or substantially all of the assets or capital stock of the Company
nor the merger or consolidation of the Company into or with any other entity, or the merger or
consolidation of any other entity into or with the Company, shall be deemed to be a

C-7

 

dissolution, liquidation or winding up, voluntary or involuntary, for the purposes of this
Section 5.

     (c) After the payment to each Series B Share of the full preferential amount provided for in
this Section 5, the Series B Shares shall have no right or claim to any of the remaining
assets of the Company.

Section 6. Ranking.

     Except as otherwise provided herein, for purposes of this resolution, any stock of any class,
classes or series of the Company shall be deemed to rank prior to the Series B Shares upon
liquidation, dissolution or winding up.

Section 7. Retirement.

     If the Series B Shares are purchased, exchanged or otherwise acquired by the Company in any
manner whatsoever, then such shares shall be retired and the certificate representing such share
shall be promptly cancelled. Upon the retirement or cancellation of the Series B Shares, such
shares shall not for any reason be reissued as a share of the Series.

Section 8. Amendment of this Certificate of Designation. 

     Any amendment, modification or repeal of any provision of this Certificate of Designation to
increase or decrease in any manner or amount the powers, designations, preferences or other rights
of the Series shall require (in addition to any vote required by law) the approval of both (i) a
majority of the Series B Directors and a majority of the Company Nominated Directors and (ii) the
majority of the Series B Shares.

Section 9. Definitions.

     Capitalized terms not otherwise defined in this Certificate of Designation shall have the
following meanings:

     “Adjustment Number” shall mean a number of shares of Common Stock (but in no event
less than zero) equal to the sum (without double counting) of: (a) the aggregate direct and
indirect short position of the Series B Holder and their Affiliates with respect to the Common
Stock, (b) the aggregate direct and indirect “put equivalent position” (as defined in Rule 16a-1(h)
under the Exchange Act) of the Series B Holders and their Affiliates with respect to the Common
Stock and (c) the number of shares of Common Stock otherwise Beneficially Owned by the Series B
Holders which have been the subject of any Indirect Disposition, reduced by (d) the aggregate
direct and indirect “call equivalent position” (as defined in Rule 16a-1(b) under the Exchange Act)
of the Series B Holders and their Affiliates with respect to the Common Stock.

     “Affiliates” means, with respect to any Person, any other Person that directly, or
indirectly through one or more intermediaries, controls, or is controlled by or under common
control with such Person. For purposes of this definition, “control” (including the terms
“controlling,” “controlled” and “under common control with”) means the
possession, direct or indirect, of the power to direct or cause the direction of the management and
policies of a Person,

C-8

 

whether through the ownership of voting securities, by contract or otherwise; provided, that
possession of ten percent (10%) of the voting securities of any Person shall be deemed to
constitute “control” for purposes of this definition.

     “Beneficially Own” and similar terms have the meaning set forth in Rule 13d-3 under
the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and
regulations promulgated thereunder; provided, that for purposes of the calculations required by
Section 3 and Section 4 the aggregate Beneficial Ownership of the Series B Holders
shall be reduced (but never increased) by the Adjustment Number.

     “Board” shall have the meaning set forth in the Preamble.

     “Business Day” means any day that is not a Saturday, a Sunday or other day on which
banks are required or authorized by law to be closed in New York, New York.

     “Bylaws” shall have the meaning set forth in the Preamble.

     “Capital Stock” means any and all shares of capital stock of the Company, including
without limitation, any and all shares of Common Stock and Preferred Stock.

     “Certificate of Incorporation” shall have the meaning set forth in the Preamble.

     “Change of Control” means any of: (a) the purchase or other acquisition by any Person
or group of Persons, directly or indirectly, in one transaction or a series of related
transactions, of Common Stock that, immediately following consummation of the transaction(s), when
combined with any other Common Stock Beneficially Owned by such Person or group, represent more
than fifty percent (50%) of the Diluted Common Shares Outstanding; (b) the consummation of any
tender offer or exchange offer by any Person or group that results in such Person or group
Beneficially Owning, when combined with any other Common Stock Beneficially Owned by such Person or
group, more than fifty percent (50%) of the Diluted Common Shares Outstanding immediately following
the consummation of such tender or exchange offer; (c) the consummation of a merger, consolidation,
amalgamation, joint venture, business combination or other similar transaction involving the
Company pursuant to which the stockholders of the Company immediately preceding such transaction
hold less than fifty percent (50%) of the voting equity interests in the surviving or resulting
entity of such transaction; or (d) the purchase or other acquisition of all or substantially all of
the assets of the Company and its subsidiaries, taken as a whole, by any Person or group of
Persons.

     “Closing”
means the close of the transactions contemplated by the Share Exchange
Agreement, by and among the Company and NXP B.V., entered into as of October 4, 2009, as amended
from time to time in accordance with its terms.

     “Common Stock” means the Common Stock, par value $0.001 per share, of the Company and
any securities issued in respect thereof, or in substitution therefor, in connection with any stock
split, dividend or combination, or any reclassification, recapitalization, merger, consolidation,
exchange or other similar reorganization.

     “Company” shall have the meaning set forth in the Preamble.

C-9

 

     “Company Nominated Directors” shall have the meaning set forth in Section
4(a)(viii).

     “Diluted Common Shares Outstanding” means the sum of (i) the number of outstanding
shares of Common Stock plus (ii) the number of shares of Common Stock issuable upon the conversion,
exercise, exchange or issuance of any other Equity Securities of the Company.

     “Director” means any member of the Board.

     “Equity Securities” means (a) any Capital Stock of the Company (including, without
limitation, Common Stock), (b) any warrants, options, or other rights to subscribe for or to
acquire, directly or indirectly, Capital Stock of the Company, whether or not then exercisable or
convertible, (c) any stock, notes, or other securities which are convertible into or exchangeable
for, directly or indirectly, Capital Stock of the Company, whether or not then convertible or
exchangeable, (d) any Capital Stock of the Company issued or issuable upon the exercise,
conversion, or exchange of any of the securities referred to in clauses (a) through (c) above, and
(e) any securities issued or issuable directly or indirectly with respect to the securities
referred to in clauses (a) through (d) above by way of stock dividend or stock split or in
connection with a combination of shares, recapitalization, reclassification, merger, consolidation,
or other reorganization.

     “Exchange” means the stock exchange on which the Company’s securities are then traded,
as the case may be. For the avoidance of doubt, The NASDAQ Stock Market, or any successor thereto,
shall constitute an Exchange for purposes of this Agreement.

     “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules
and regulations promulgated thereunder.

     “Independent Director” shall mean a Director who is independent of the Company under
applicable law and the rules of the Exchange.

     “Indirect Disposition” shall mean any forward sale, option, swap, hedge, put/call
arrangement or other transaction by which such Person has conveyed (in whole) the right or ability
to realize profit or loss based on changes in the trading price of the Common Stock or other Equity
Security, whether settlement under any such transaction is to be made in cash, by delivery of
securities, or otherwise; provided, that hedging or collar transactions under which such Person
retains the opportunity for gain and risk of loss arising from price changes of no less than
fifteen percent (15%) from the trading price of the Common Stock at the time of any such
transaction shall not constitute Indirect Dispositions.

     “Liquidation Preference” shall have the meaning set forth in Section 1.

     “Own” and “Ownership” shall mean, with respect to any Person and any Series B
Shares, that such Person is the record owner of such Series B Shares.

     “Person” means any natural person, corporation, limited liability company, trust,
joint venture, association, company, partnership, governmental authority or other entity.

     “Preferred Stock” shall have the meaning set forth in the Preamble.

C-10

 

     “SEC” means the U.S. Securities and Exchange Commission or any other federal agency
then administering the Securities Act or the Exchange Act and other federal securities laws.

     “Securities Act” means the Securities Act of 1933, as amended, and the rules and
regulations promulgated thereunder.

     “Series” shall have the meaning set forth in Section 1.

     “Series B Director” shall have the meaning set forth in Section 4(a)(i).

     “Series B Holder” shall have the meaning set forth in Section 1.

     “Series B Share” shall have the meaning set forth in Section 1.

     “Stockholder Agreement” means the Stockholder Agreement, by and between the Company
and NXP B.V., entered into as of February 8, 2010, as amended from time to time in accordance with
its terms.

Section 10. Descriptive Headings and Governing Law.

     The descriptive headings of the several Sections and paragraphs of this Amended and Restated
Certificate of Designation are inserted for convenience only and do not constitute a part of this
Amended and Restated Certificate of Designation. The General Corporation Law of the State of
Delaware shall govern all issues concerning this Amended and Restated Certificate of Designation.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

C-11

 

     IN WITNESS WHEREOF, Company has caused this Amended and Restated Certificate of Designation to
be signed by its duly authorized officer this __th day of _____, 2011.

	 	 	 	 	 
	 	TRIDENT MICROSYSTEMS, INC.

 	 
	 	By:  	/s/ David L. Teichmann
 	 
	 	 	Name:  	David L. Teichmann 	 
	 	 	Title:  	Executive Vice President, General Counsel and
Corporate Secretary 	 
	 

C-12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00188-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00188-of-00352.parquet"}]]